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ABSTRACT 
Hepatitis C was first recognized as a transfusion-associated liver disease not caused by 
hepatitis A or hepatitis B virus after serological tests were developed to screen for their 
presence in the blood.  The infectious agent was finally identified with the cloning of the cDNA of 
hepatitis C virus (HCV) using random polymerase chain reaction (PCR) screening of nucleic 
acids extracted from plasma of a large pool of chimpanzee infected with non-A non-B hepatitis. 
NS5B, a membrane-associated RNA-dependent RNA polymerase essential in the 
replication of HCV, initiates the synthesis of a complementary negative-strand RNA from the 
genomic positive-strand RNA so that more positive-strand HCV RNA can then be generated 
from the newly synthesised negative-strand template.  The crystal structure of NS5B presented 
typical fingers, palm and thumb sub-domains encircling the GDD active site, which is also seen 
in other RNA-dependent RNA polymerases, and is similar to the structure of reverse 
transcriptase of HIV-1 and murine Moloney leukaemia virus.  The last 21 amino acids in the C-
terminus of NS5B anchor the protein to the endoplasmic reticulum (ER)-derived membranous 
web.  NS5B has been shown to interact with the core, NS3/NS4A, NS4B and NS5A proteins, 
either directly or indirectly.  Numerous interactions with cellular proteins have also been 
reported.  These proteins are mainly associated with genome replication, vesicular transport, 
protein kinase C-related kinase 2, P68 (DDX5), α-actinin, nucleolin, human eukaryotic initiation 
factor 4AII, and human VAMP-associated protein. 
Previous studies have confirmed that NS5B binds to full-length DDX5.  By constructing 
deletion mutants of DDX5, we proceeded to characterize this interaction between DDX5 and 
HCV NS5B.  We report here the identification of two exclusive HCV NS5B binding sites in 
DDX5, one in the N-terminal region of amino acids 1 to 384 and the other in the C-terminal 
region of amino acids 387 to 614.  Proteins spanning different regions of DDX5 were expressed 
and purified for crystallization trials.  The N-terminal region of DDX5 from amino acids 1 to 305 
which contains the conserved domain I of the DEAD-box helicase was also cloned and 
 
 
 
 
vi 
 
expressed in Escherichia coli.  The cloning, expression, purification and crystallization 
conditions are presented in this work. 
Subsequently, the crystal structure of DDX5 1-305 was solved and the high resolution 
three-dimensional structure shows that in front of domain I is the highly variable and disordered 
N terminal region (NTR) of which amino acids 51-78 is observable, but whose function is 
unknown.  This region forms an extensive loop and supplements the core with an additional -
helix.  Co-immunoprecipitation experiments demonstrated that the NTR of DDX5 1-305 auto-
inhibit its interaction with NS5B.  Interestingly, the -helix in NTR is essential for this auto-
inhibition and seems to mediate the interaction between the highly flexible 1-60 residues in NTR 
and NS5B binding site in DDX5 1-305, presumably located within residues 79-305.  
Furthermore, co-immunoprecipitation experiments revealed that DDX5 can also interact with 
other HCV proteins, besides NS5B. 
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1.1 Introduction 
Hepatitis C was first recognized as a transfusion-associated liver disease not caused by 
hepatitis A or hepatitis B virus after serological tests were developed to screen for hepatitis A 
and hepatitis B in the blood (Prince, Brotman et al. 1974; Feinstone, Kapikian et al. 1975).  The 
infectious agent was finally identified with the cloning of the cDNA of the hepatitis C virus (HCV), 
using random polymerase chain reaction (PCR) screening of nucleic acids extracted from 
plasma of a large pool of chimpanzee infected with non-A non-B hepatitis (Choo, Kuo et al. 
1989). 
HCV is recognized as a major aetiological agent of liver disease as it infects 3% of the 
world’s population, or more than 170 million people worldwide (Wasley and Alter 2000).  In 20-
30% of patients, HCV infection is acute and the virus is cleared naturally (Alter and Seeff 2000).  
However, in the majority of cases, the virus persists, often predisposing infected individuals to 
fibrosis, cirrhosis and hepatocellular carcinoma (Macdonald and Harris 2004).  A recent study 
proposed that chronic HCV infection increases insulin resistance leading to an increased 
chance of developing type 2 diabetes (Kasai, Adachi et al. 2009). 
The broad genetic diversity amongst HCV genotypes and the high rate of mutations 
during replication makes it a challenging disease to treat.  No effective vaccine has been 
developed against HCV infection (Lechmann and Liang 2000).  The current therapy for HCV 
infection involves the use of a combination of polyethylene (PEG)-conjugated interferon alpha 
(IF-α) and ribavirin.  These drugs are expensive and produce severe side effects such as 
headache, myalgia, fever, depression, arthralgia and haemolytic anaemia (De Franceschi, 
Fattovich et al. 2000; Hayashi and Takehara 2006).  Moreover, this drug treatment is only 
effective in eradicating the virus in approximately 50% of infected patients and the efficacy 
varies with different viral genotypes (Hayashi and Takehara 2006; Ghany, Strader et al. 2009). 
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1.2 Hepatitis C Virus Genome 
HCV is a member of the Flaviviridae family of viruses which includes flavivirus, pestivirus and 
hepacivirus.  Flaviviruses include dengue fever virus, Japanese encephalitis virus, tick-borne 
encephalitis virus and yellow fever virus.  Pestiviruses include bovine viral diarrheoa virus, 
border disease virus and classical swine fever virus (Tan and National Center for Biotechnology 
2006).  HCV is a small, enveloped, positive-strand RNA virus and is the only representative of 
hepacivirus.  The 9.6 kb RNA molecule comprises the 5’ and 3’ untranslated regions (UTR) 
flanking a single open reading frame (ORF) encoding a polyprotein of approximately 3000 
amino acids (Figure 1.1).  
1.3 Hepatitis C Virus Proteins 
HCV viral protein is first translated as a polyprotein precursor via an internal ribosome entry site 
located in the 5’-UTR.  This polyprotein is then cleaved into 10 polypeptides by cellular and viral 
proteinases.  The N- terminus encodes three structural proteins – core, envelope glycoproteins 
E1 and E2, while the C-terminal two-thirds of the polyprotein comprise the 6 non-structural 
proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B (Macdonald and Harris 2004).  These 
proteins encode enzymes or accessory factors that catalyse and regulate the replication of the 
HCV RNA genome (Tan, Pause et al. 2002).  Another protein, called p7, lies at the junction 
between the structural and non-structural regions of the virus polyprotein. 
1.3.1 The Core Protein 
The core protein interacts with viral RNA and forms the nucleocapsid (Tan, Pause et al. 2002).  
It has also been shown to be functionally pleiotropic, interacting with many cellular proteins and 
exerting an array of effects on cells such as apoptosis, lipid metabolism, transcription, cellular 
transformation and the immune response (Marusawa, Hijikata et al. 1999); (Moriya, Fujie et al. 
1998); (Ray, Lagging et al. 1995); (Ray, Lagging et al. 1996); (Large, Kittlesen et al. 1999). 
When expressed in transfected cells, the protein was found to associate with cellular lipid 
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storage droplets (Barba, Harper et al. 1997).  Depending on the proteolytic processing, the core 
protein exists as two forms in all HCV strains, known as p21 and p23 according to their 
molecular weights (Figure 1.2) (Yasui, Wakita et al. 1998).  A third core-related protein species, 
termed p16, has also been detected in studies using HCV-1 (Figure 1.2) (Lo, Masiarz et al. 
1995).  The functions of these protein species are still unknown, although p21 has been 
suggested to be the mature form that constitutes the virus capsid (Yasui, Wakita et al. 1998).  
The core protein was found to self-assemble into virus-like particles in the endoplasmic 
reticulum (ER) membrane (Ait-Goughoulte, Hourioux et al. 2006). 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic representation of the HCV genome and encoded viral proteins (Tan, 
Pause et al. 2002).  The boxed area corresponds to the single ORF of the HCV genome.  The 
stem–loop structures represent the 5′ and 3′ non-translated (NTR) regions, including the internal 
ribosome-entry site (IRES) and 3′-X-regions.  The function and molecular mass (in kDa) of the 
gene products after polyprotein processing are shown.  Core (C)–E1, E1–E2, E2–p7 and p7–non-
structural protein 2 (NS2) junctions are cleaved by cellular signal peptidases to yield structural 
proteins.  The NS2–NS3 metalloproteinase undergoes autocatalytic cleavage, which releases the 
mature NS3 serine protease.  NS3 cleaves the remainder of the NS polypeptide.  The two regions 
that have extreme sequence variability in E2, known as hypervariable regions 1 and 2 (HVR1 and 
HVR2), are indicated.  A region in NS5A, known as the interferon (IFN)-sensitivity-determining 
region (ISDR), has been linked to the response to IFN-α therapy in some strains of HCV.  Both 
NS5A and E2 have been implicated as antagonists of IFN.  ARFP/F: alternative reading-frame 
protein/frameshift protein; LDLR: low-density lipoprotein receptor; RdRp: RNA-dependent RNA 
polymerase. 
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Figure 1.2: Schematic representation of the three core protein species. The P23, P21 and 
P16 core proteins with sizes (number of amino acids) shown.  
 
1.3.2 Envelope Glycoproteins E1 and E2 
Envelope glycoproteins E1 and E2, together with the core protein, are components of the viral 
particle (Voisset and Dubuisson 2004).  The E2 protein binds CD81, a tetraspan protein 
expressed on various cell types including hepatocytes and B lymphocytes.  E2 binding to 
human CD81 was mapped to the major extracellular loop of CD81 (Pileri, Uematsu et al. 1998).  
Both E1 and E2 are important for the binding of HCV to cellular receptor(s) on the surface of 
host cells such as hepatocytes, and are possibly responsible for the binding to and entry of the 
virus into target cells (Tan, Pause et al. 2002); (Suzuki, Suzuki et al. 1999).  CD81, human 
scavenger receptor, SR-BI, tight junction claudin-1 and occludin are the most important 
receptors mediating HCV cell entry (Ploss, Evans et al. 2009).  
1.3.3 Ion Channel p7 
It has been shown that p7 forms an amantadine-sensitive ion channel required for viral 
replication in chimpanzees, though its precise role in the life cycle of HCV is unknown (Sakai, 
Claire et al. 2003).  However, clinical trials found that the p7 ion channel function is not affected 
by amantadine (Steinmann, Whitfield et al. 2007).  The p7 polypeptide of HCV is critical for 
infectivity and contains functionally important genotype-specific sequences (Griffin, Harvey et al. 
2004).  
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1.3.4 Zinc Metalloproteinase NS2 
The zinc metalloproteinase, NS2-NS3, undergoes autocatalytic cleavage to produce NS2 and 
NS3.  NS2 intercts with other non-structural proteins and forms homodimers with itself 
(Dimitrova, Imbert et al. 2003).  It was found to be an apoptosis inhibitor and interferes with 
cellular gene expression (Dumoulin, von dem Bussche et al. 2003); (Erdtmann, Franck et al. 
2003).  A recent study has shown that NS2 plays an essential role in HCV particle assembly by 
interacting with E1 and E2 glycoproteins as well as NS3-NS4 enzyme complexes (Stapleford 
and Lindenbach 2011).    
1.3.5 Serine Protease NS3 
NS3 is a serine protease with nucleoside triphosphatase and RNA helicase activity at its C-
terminus (Tan, Pause et al. 2002).  NS3 cleaves the remaining nonstructural polyprotein to 
produce NS4A, NS4B, NS5A and NS5B.  When singly expressed, NS3 protein had been shown 
to be distributed to the cytoplasm and nucleus in an inducible system (Wolk, Sansonno et al. 
2000).  The NS3 protease, together with its cofactor NS4A, stops the expression of interferon 
alpha (IF-α) and interferon beta (IF-ß) by cleaving the IF-ß promoter stimulator-1 and thus 
evading the innate immune system (Li, Sun et al. 2005).     
1.3.6 Modulating Cofactor NS4A 
NS4A serves as a cofactor modulating NS3 serine protease and helicase activities, and is 
responsible for localizing NS3 to the perinuclear ER membrane (De Francesco and Steinkuhler 
2000); (Pang, Jankowsky et al. 2002); (Wolk, Sansonno et al. 2000).  NS4A also associates 
with NS5A and contributes to hyperphosphorylation of NS5A (Asabe, Tanji et al. 1997).  
Expression of NS4A was found to significantly change the intracellular distribution of 
mitochondria, thus resulting in mitochondrial damage and inducing apoptosis (Nomura-
Takigawa, Nagano-Fujii et al. 2006).  
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1.3.7 Integral ER Membrane Protein NS4B 
NS4B is a hydrophobic integral ER membrane protein with four transmembrane (tetraspan) 
segments (Suzuki, Suzuki et al. 1999); (Hugle, Fehrmann et al. 2001).  The protein has been 
shown to induce a specialized membranous web postulated to be the HCV RNA replication 
complex (Egger, Wolk et al. 2002).  
1.3.8 Phosphoprotein NS5A 
Phosphoprotein NS5A is a pleiotropic protein with key roles in viral RNA replication and 
modulation of host cell physiology (Macdonald and Harris 2004).  It co-localises with the viral 
RNA and other non-structural proteins in the cytoplasmic membranous web that catalyse viral 
genome replication (Macdonald and Harris 2004); (Mottola, Cardinali et al. 2002).  By binding to 
a range of cellular signalling molecules, NS5A modulates a range of physiological process such 
as HCV resistance to IFN therapy, cell growth and apoptosis (Tan, Pause et al. 2002; 
Macdonald and Harris 2004).  
1.3.9 Membrane-Associated RNA-Dependent RNA Polymerase NS5B 
NS5B is a membrane-associated RNA-dependent RNA polymerase (Behrens, Tomei et al. 
1996; Suzuki, Suzuki et al. 1999).  It plays an essential role in the replication of HCV, it initiates 
the synthesis of a complementary negative-strand RNA from the genomic positive-strand RNA, 
more positive-strand HCV RNA can then be generated from the newly synthesised negative-
strand template.  The crystal structure of NS5B presented typical fingers, palm and thumb sub-
domains encircling the GDD active site, which is also seen in other RNA-dependent RNA 
polymerases and is similar to the structure of reverse transcriptase of HIV 1 and murine 
Moloney leukaemia virus (Bressanelli, Tomei et al. 1999).  The last 21 amino acids in the C-
terminal of NS5B anchor the protein to the ER-derived membranous web (Schmidt-Mende, 
Bieck et al. 2001).  
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NS5B has been shown to interact with the core, NS3/NS4A, NS4B and NS5A proteins 
either directly or indirectly (Lee, Nam et al. 2006).  Numerous interactions with cellular proteins 
have also been reported.  These proteins are mainly proteins associated with genome 
replication, as well as vesicular transport, such as protein kinase C-related kinase 2, P68 
(DDX5), α-actinin, nucleolin, human eukaryotic initiation factor 4AII, and human VAMP-
associated protein (Lee, Nam et al. 2006).  NS5B is widely targeted in the development of 
antiviral therapy due to its essential role in viral replication.  Many nucleoside analogues that act 
as chain terminators target the active site of the polymerase.  Non-nucleoside inhibitors that act 
by binding to one of the four allosteric enzyme sites inhibit polymerase activity (Legrand-
Abravanel, Nicot et al. 2010).  Due to a lack of proofreading in RNA replication, there is a pre-
existence of quasi species in HCV-infected individuals.  The selection of species resistant to 
specific antiviral therapy over time is of major concern.  The discovery that cyclosporine A 
inhibits HCV replication by binding cyclophilin, a host cellular peptidyl-prolyl isomerase that 
interacts with NS5B, provides a new avenue for future of drug therapy that target a host factor 
that interacts with the virus (Chatterji, Bobardt et al. 2009).   
1.4 Animal Models  
Chimpanzee is the only established animal model for HCV infection, but due to the scarcity of 
the animal, high cost of maintenance, and ethical and conservation concerns, efforts have been 
made to establish a small animal model to study HCV infection and liver disease caused by 
HCV infection.  The tree shrew (Tupaia sp.) represents the only non-primate small animal model 
for HCV infection.  The tree shrew was successfully infected with HCV after severe 
immunosuppression (Xie, Riezu-Boj et al. 1998) and more recently, chronic infection were 
observed in some of the normal adult tree shrews infected with HCV (Xu, Chen et al. 2007).  
The HCV virus is able to replicate in transgenic mice transplanted with human hepatocytes 
(Mercer, Schiller et al. 2001).  Transgenic mice expressing HCV genes in the liver have been 
used in the study of hepatocellular carcinoma (Moriya, Fujie et al. 1998). 
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1.5 HCV Replicons  
HCV is inefficient in infecting cultured cells and produce very low titers.  Efforts to identify cell 
lines which could produce robust infection and virus production was not successful 
(Bartenschlager and Lohmann 2001) until the advent of HCV subgenomic replicons (Lohmann, 
Korner et al. 1999) based on knowledge gained from the development of subgenomic replicons 
of pestivirus and Kunjin virus (Khromykh and Westaway 1997; Behrens, Grassmann et al. 
1998).  Using the consensus sequence of HCV genotype 1b termed Con1 as template, the 
structural protein region was replaced by a neomycin phosphotransferase gene, conferring 
G418 resistance and the expression of non-structural proteins was controlled by the internal 
ribosomal entry site (IRES) of encephalomyocarditis virus (EMCV).  Transfection of the 
constructs into human hepatoma Huh 7 cells produced colonies that could autonomously 
replicate under neomycin selection.  The subgenomic replicon helped identify amino acid 
substitutions (adaptive mutations in cell culture) that increased replication efficiency by several 
orders of magnitude (Blight, Kolykhalov et al. 2000; Lohmann, Korner et al. 2001).   
The development of a full-length HCV genome 1b replicon enabled the study of antiviral 
agents against HCV structural proteins that were missing in the subgenomic replicon (Blight, 
McKeating et al. 2002; Ikeda, Yi et al. 2002; Pietschmann, Lohmann et al. 2002).  Subsequent 
development of HCV RNA replicons of genotype 1a (Blight, McKeating et al. 2003) and 2a 
(Kato, Date et al. 2003) and replicons that were able to replicate in human embryonic kidney 
cells, non-hepatic epithelial and mouse hepatoma cells provided new insights into genotype-
specific replication and the development of quasi species in HCV-infected individuals (Zhu, Guo 
et al. 2003; Ali, Pellerin et al. 2004).  The replicon system enables the efficient study of HCV 
RNA replication in vitro, shedding light on basic replication processes, structure of the 
replication complex, virus interactions with the host cell and effects of antiviral agents (Brass, 
Moradpour et al. 2007; Dustin and Rice 2007).   
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1.6 Production of Infectious Hepatitis C Virions in Tissue Culture  
The replicons of genotype 1a, 1b and 2a molecular clones revolutionised the study of basic 
HCV replication in cell culture, but they did not produce infectious virions.  While adaptive 
mutations were advantageous for replicon replication in cell culture, they could be deleterious 
for virus production (Lanford, Lee et al. 2001; Lindenbach and Rice 2005).  The development of 
a genotype 2a HCV replicon derived from the consensus sequence of a virus isolated from a 
Japanese patient with fulminant hepatitis denoted as JFH-1 (Wakita, Pietschmann et al. 2005), 
overcame the inability to study virus entry and release in a tissue culture.  The JFH-1 replicon 
was able to replicate efficiently in different cell lines and secreted viral particles that were 
infectious in chimpanzees and could be subcultured to infect naïve Huh 7 cells (Lindenbach and 
Rice 2005).  A chimaeric full-length HCV genomic construct of JFH-1 was cloned by replacing 
the Core-NS2 region with that of the J6 strain of genotype 2a.  The new full-length J6/JFH clone 
replicated even more efficiently in cell culture producing 105 infectious units per milliliter within 
48 hours in Huh 7.5 cells (Lindenbach, Evans et al. 2005).  
Liver cirrhosis and cancer associated with HCV infection are normally caused by 
genotype 1 HCV.  Hence, the development of an infectious HCV of genotype 1 was significant.  
The first genotype 1a infectious clone boasted 5 cell culture adapted mutations and specificity 
that were approximately 400-fold lower than that of genotype 2a virus (Yi, Villanueva et al. 
2006).  Infectious intragenotypic and intergenotypic HCV chimeras of genotype 1a, 1b, 2a and 
3a were also developed and characterised (Pietschmann, Kaul et al. 2006).  The development 
of more infectious HCV of different genotypes will broaden the tools available for antiviral and 
comparative life cycle investigations. 
1.7 Helicases  
Helicases are vital enzymes involved in all aspects of DNA and RNA metabolism.  They use 
energy derived from binding and hydrolysing ATP to unwind double stranded nucleic acids 
(Lohman 1993; Hall and Matson 1999).  DNA helicases are involved in DNA replication, 
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transcription, conjugation, recombination and repair (Lahue and Matson 1988; Lohman and 
Bjornson 1996).  They are processive in their activity (Lahue and Matson 1988; Roman, 
Eggleston et al. 1992; Lohman 1993; Sikora, Eoff et al. 2006), binding to regions where breaks 
in the base pairing form single stranded DNA and double stranded DNA junctions, they proceed 
to unwind double stranded DNA (Amaratunga and Lohman 1993).  Earlier studies proposed that 
DNA helicases unwound double stranded DNA unidirectionally (3’ to 5’ or 5’ to 3’) (Lohman 
1993; Yu, Ha et al. 2007), in either an active or passive manner (Lohman 1993).  During passive 
DNA unwinding, helicase bound to single stranded DNA at a single strand double strand DNA-
junction translocate stepwise along the single stranded DNA preventing the duplex from 
reforming when random thermal fluctuations opens up the base pairs.  In active DNA unwinding, 
helicase binds to both single stranded and double stranded DNA at the single strand-double 
strand DNA junction, unwinding the DNA by destabilising the base-pairing using energy derived 
from ATP hydrolysis (Lohman 1992; Amaratunga and Lohman 1993; Lohman 1993).  More 
recent theoretical and experimental studies are in favour of a mechanism whereby the 
energetics involved in helicase activity form a continuum (Betterton and Julicher 2005; Johnson, 
Bai et al. 2007). 
RNA helicases represent a multifunctional group of proteins.  Besides their traditional 
role of using energy derived from binding and hydrolysis of ATP to unwind RNA duplexes, they 
have been known to function as chaperones that rearrange RNA structures and modify RNA-
associated protein complexes (Tanner and Linder 2001; Cordin, Banroques et al. 2006; 
Bleichert and Baserga 2007).  Involved in all aspects of RNA metabolism, they are required 
during transcription, pre-mRNA splicing, ribosome biogenesis, mRNA nuclear export, translation 
initiation and RNA degradation (Cordin, Banroques et al. 2006; Linder 2006).    
1.7.1 Transcription 
RNA helicases facilitate and regulate gene expression. DP103 (Ddx20) was shown to interact 
and suppress the transcriptional activity of steroidogenic factor 1 (SF-1) and Egr2 (Yan, Mouillet 
et al. 2003; Gillian and Svaren 2004).  RNA helicase A (Dhx9) regulates transcription by acting 
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as a bridging factor between cAMP-response element-binding protein and RNA polymerase II 
(Nakajima, Uchida et al. 1997).  p68 (Ddx5) and related p72 (Ddx17) interacts with different 
transcription factors and nuclear receptors as co-repressors or co-activators of transcription 
(Endoh, Maruyama et al. 1999; Watanabe, Yanagisawa et al. 2001; Wilson, Bates et al. 2004; 
Cordin, Banroques et al. 2006). 
1.7.2 Pre-mRNA Splicing 
Spliceosomes are formed by large ribonucleoprotein (RNP) complexes.  They assemble and go 
through modification while the transcribed pre-mRNAs are processed.  The removal of introns 
by two transesterification reactions to form mature mRNAs ready for export, and the subsequent 
release of the mRNA from the spliceosomes require precise rearrangement of the RNP 
complexes (Staley and Guthrie 1998; Cordin, Banroques et al. 2006; Linder 2006; Abdelhaleem 
2010).  RNA helicase p68 is essential in pre-mRNA splicing and is required for the dissociation 
of U1 small nuclear ribonucleoprotein (snRNP) from the 5’ splice site (Liu 2002; Lin, Yang et al. 
2005).  Prp2 (Kim and Lin 1996) and Prp16 (Schwer and Guthrie 1991) serve as catalysts to the 
first and second transesterification steps while Prp22 disrupts mRNA/U5 snRNP contacts to 
release mRNA from the spliceosome (Schwer 2008) and Prp43 catalyses the removal of the 
lariat-intron  (Martin, Schneider et al. 2002).  
1.7.3 Ribosome Biogenesis 
Ribosome biogenesis is a complex process that involves transcription, modification and 
processing of ribosomal RNA (rRNA) with interactions with ribosomal proteins and a variety of 
transacting factors.  RNA helicases are required during ribosome biogenesis, regulate RNA-
protein interactions in the ribosomes (de la Cruz, Kressler et al. 1999; Cordin, Banroques et al. 
2006; Linder 2006; Abdelhaleem 2010).  
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1.7.4 Nuclear Export 
Mature mRNAs are exported through the nuclear pore into the cytoplasm for translation in 
eukaryotic cells.  Dba5p was shown to be essential for nuclear export as mutation of Dbp5 
resulted in accumulation of poly(A)+ RNA in the nucleus (Tseng, Weaver et al. 1998).  DDX3, a 
human RNA helicase, acts as a shuttle between the nucleus and cytoplasm and is essential for 
HIV-1 RNA export (Yedavalli, Neuveut et al. 2004). 
1.7.5 Translation  
Eukaryotic initiation factor 4A (eIF4A) is an RNA helicase with RNA-dependent ATPase activity.  
It forms part of the cap-binding complex of eIF4F involved in the initiation of translation 
(Gingras, Raught et al. 1999), and is probably involved in the unwinding of secondary structure 
in the 5’-untranslated region of mRNA which hinders ribosome binding (Rogers, Komar et al. 
2002).  Ded1 in yeast (Chuang, Weaver et al. 1997; Tarn and Chang 2009) and Vasa in 
Drosophila (Carrera, Johnstone et al. 2000) have also been shown to be crucial for translation. 
1.7.6 Degradation 
In eukaryotes, different exosomes are responsible for degradation of small regulatory RNAs, 
defective mRNAs and mRNAs in the nucleus, cytoplasm and mitochondria (Cordin, Banroques 
et al. 2006).  RNA helicase Mtr4p forms part of the Trf4p/Air2p/Mtr4p polyadenylation complex 
(TRAMP), responsible for polyadenylation and stimulation of exosome degradation of RNA in 
the nucleus (LaCava, Houseley et al. 2005), while Ski2 is required for cytoplasmic exosomes 
activity responsible for 3’ to 5’ mRNA degradation in yeast (Anderson and Parker 1998).  Upf1 is 
critical in the nonsense-mediated mRNA decay pathway whereby mRNA with premature 
termination codons are recognized and degraded (Cheng, Muhlrad et al. 2007), while RHAU 
plays a part in the degradation of AU rich elements in mRNA (Tran, Schilling et al. 2004). 
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1.7.7 Conserved Motifs of Helicases 
Primary sequence analysis were first used to identify helicases with conserved motifs and 
categorised them into 3 superfamiles and 2 families (Gorbalenya and Koonin 1993).  All the 
helicases identified carried the WaIker A (phosphate-binding loop) and Walker B (Mg2+-binding 
aspartic acid) motifs (Walker, Saraste et al. 1982).  The majority of helicases identified fell into 
the superfamily 1 (SF1) and superfamily 2 (SF2) classification (Gorbalenya and Koonin 1993).  
A classic member of SF2, eIF4A was the first RNA helicase reported to have the ability to 
change the structure of mRNA using energy supplied from ATP - it was shown that incubation of 
globin mRNA with eIF4A changed the mRNA sensitivity to nuclease (Ray, Lawson et al. 1985).  
Alignment studies of yeast eIF4A with its homologues contributed to the identification of the 
DEAD box family of proteins with the distinct D-E-A-D (Asp-Glu-Ala-Asp) amino-acid sequence 
at its Walker B motif (Linder, Lasko et al. 1989). 
1.7.8 The DEAD-Box Helicases 
The DEAD–box family of helicases are ubiquitous and play major roles in RNA metabolism (de 
la Cruz, Kressler et al. 1999; Rocak and Linder 2004; Abdelhaleem 2010).  They are 
distinguished by 9 conserved motifs: the Q-motif, motif I, motif Ia, motif Ib motif II and motif III 
forms the N-terminal domain I, while motif IV, motif V and motif VI form the C-terminal domain II 
(Figure 1.3).  A conserved sequence of GG is found between Ia and Ib and a conserved 
sequence QxxR (x is any residue) is found between motifs IV and V.  The Q-motif together with 
a conserved phenylalanine upstream of it sets it apart from the other closely related DEAH, 
DExH and DExD families of proteins (Tanner, Cordin et al. 2003; Cordin, Banroques et al. 2006; 
Bleichert and Baserga 2007).  The conserved motifs are involved in the regulation of helicase 
and ATPase activities (Tanner, Cordin et al. 2003).   
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Figure 1.3: Structure of full-length eIF4A helicase showing the conserved motifs of domains 
I and II (Caruthers et al., 2000; PDB accession number: 1FUU).  Domain I on the left contains 
the conserved Q-motif, motif I, motif Ia, the conserved GG sequence, motif Ib, motif II and motif III.  
Domain II on the right holds conserved motifs IV, V and VI.    
 
1.7.8.1 Significance of Conserved Motives in DEAD-Box Proteins 
Solved crystal structures of MjDEAD the DEAD-box protein of Methanococcus jannashii (Story, 
Li et al. 2001), UAP56 - a human splicing and export factor (Shi, Cordin et al. 2004), yeast 
mRNA translation and degradation factor Dhh1p (Cheng, Coller et al. 2005), human elongation 
factor 4AIII (eIF4AIII) (Andersen, Ballut et al. 2006; Bono, Ebert et al. 2006), and human DEAD-
box helicase DDX3X (Hogbom, Collins et al. 2007) show that domains I and II are connected via 
a short flexible linker.  Each globular domain consists of at least 5 α-helices flanking 5 β-
strands, corresponding to the core structure of Rec A (Story and Steitz 1992; Caruthers and 
McKay 2002; Cordin, Banroques et al. 2006).  
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1.7.8.2 Q Motif 
Sequence alignment analysis of yeast eIF4A with other related DEAD box proteins resulted in 
the identification of a 9 amino acid motif and a highly conserved aromatic residue phenylalanine 
(F) upstream of motif I.  The consensus sequence defined for this motif was GaccPohlQ, where 
a represents an aromatic residue, c: a charged group, o: an alcohol, h: a hydrophobic group and 
I: an aliphatic residue.  The Q motif was thus named after the glutamine residue that was 
conserved in 99% of the sequences.  In solved structures of DEAD-box proteins, the Q motif 
and the aromatic residue 17 amino acids upstream of it shows up as an extra β-strand and 2 α-
helices forming a cap-like structure on domain I (Figure 1.4) (Tanner, Cordin et al. 2003; Cordin, 
Tanner et al. 2004; Cordin, Banroques et al. 2006).  The Q motif is a conserved adenine 
recognition motif needed for adenine binding - it interacts with motif I during ATP and RNA 
binding and regulates ATPase activity (Tanner 2003; Cordin, Tanner et al. 2004). 
1.7.8.3 Motif I 
Motif I (AxTGoGKT) was first described as the Walker A motif, which was found in all helicases 
and many NTPases (Walker, Saraste et al. 1982).  It forms the phosphate-binding P-loop 
responsible for nucleotide binding and is essential for ATPase and helicase activity.  In 
nucleotide-bound structures of eIF4A and UAP56, the helix formed by motif I was found in an 
unwound “open” conformation (Benz, Trachsel et al. 1999; Story, Li et al. 2001; Shi, Cordin et 
al. 2004; Zhao, Shen et al. 2004).  In eIF4A, UAP56 and BstDEAD crystallised without a ligand, 
the P-loop was found in a “closed” conformation (Johnson and McKay 1999; Carmel and 
Matthews 2004; Shi, Cordin et al. 2004).   
1.7.8.4 Motif Ia and Motif Ib 
Motifs Ia (PTRELA) and Ib (TPGR) form part of domain I, but they have not been observed to 
participate directly in ATP binding or hydrolysis.  They have, however, been shown to be crucial 
for RNA binding, acting in conjunction with motifs IV and V (Rogers, Komar et al. 2002).  Motif Ia 
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has also been found to be essential for formation of an exon-junction complex and nonsense 
mediated mRNA decay (Shibuya, Tange et al. 2006).   
 
 
 
 
 
 
 
 
 
Figure 1.4: Schematic representation of conserved motifs of yeast eIF4A (adapted from 
Cordin, Tanner et al. 2004).  A. The positions of the conserved motifs are shown (Tanner and 
Linder, 2001).  B. Enlargement of the region containing the upstream phenylalanine, the Q motif, 
and the previously characterized motif I.  The numbers below refer to the positions of the amino 
acids in eIF4A.  The consensus is based on the same alignment as in (A), but the conservation of 
amino acids (uppercase) and functional groups (lowercase) are shown (a: F, W, Y; c: D, E, H, K, R; 
l: I, L, V; o: S, T; x: any amino acid).  The glutamine is 17 aa upstream of motif I 88% of the time 
(range 14–32 aa), and the isolated aromatic group is 17 aa upstream of the Q motif 82% of the 
time (range 12–20 aa). 
1.7.8.5 Motif II 
Motif II (also known as Walker B motif) is necessary for ATPase activity.  The majority of DEAD-
box proteins carry the signature sequence of DEAD in this motif (Tanner and Linder 2001), 
while the consensus sequence of DExx is found in other SF1 and SF2 proteins (Gorbalenya and 
Koonin 1993).  Mutations in this region have been shown to decrease or abolish NTPase and 
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helicase activity without affecting RNA binding (Pause and Sonenberg 1992; Iost, Dreyfus et al. 
1999).  The glutamine residue of motif II forms interaction with the β and γ phosphates of bound 
ATP through a coordinated magnesium ion and may be involved in hydrolysis (Story, Li et al. 
2001; Shi, Cordin et al. 2004; Cordin, Banroques et al. 2006). 
1.7.8.6 Motif III 
Motif III (SAT) is highly conserved in SF2 helicases.  It was proposed to link ATP binding and 
helicase activities.  Earlier studies showed that mutations in this motif affected substrate 
unwinding, but not ATP binding and hydrolysis (Pause and Sonenberg 1992; Schwer and 
Meszaros 2000).  A recent study of  Ded1 reviewed that mutations in Motif III affected RNA 
dependent hydrolysis of ATP and reduced its binding affinity of single-stranded  RNA, but the 
affinity for ATP is not affected (Banroques, Doère et al. 2010).  The role of motif III may differ 
amongst helicases.  
1.7.8.7 Motif IV 
It has been proposed that motif IV is bound to RNA through interactions with the ribose-
phosphate backbone (Caruthers and McKay 2002).  Located at the bottom of domain II, the 
consensus sequence of motif IV is 2 aliphatic groups, a phenylalanine and a hydrophobic group 
followed by 5 polar and charged groups.  The phenylalanine is the only residue that is 
conserved at 98% in this motif, and plays a crucial role in linking ATP binding and hydrolysis 
with RNA binding (Banroques, Cordin et al. 2008). 
1.7.8.8 Motif V 
Motif V is involved in RNA binding and unwinding and stimulates ATPase activity (Caruthers, 
Johnson et al. 2000; Schneider, Campodonico et al. 2004).  Situated between Domain I and II, 
motif V is crucial in conformational change that closes the inter-domain cleft which affects ATP 
binding, hydrolysis and RNA unwinding (Karow and Klostermeier 2009).   
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1.7.8.9 Motif VI 
Situated at the interface between domain I and domain II, motif VI (HRIGRTGR) of the DEAD-
box proteins was shown to be critical for RNA binding and ATP hydrolysis (Pause, Methot et al. 
1993; Rogers, Komar et al. 2002).  It was proposed that the first and second arginines in motif 
VI bound to the γ-phosphate of ATP and the second arginine was essential to ATP binding and 
hydrolysis (Caruthers, Johnson et al. 2000). 
1.8 Aim of this Study 
To ensure productive infections, viruses need to manipulate and/or alter the host cell’s biological 
mechanisms.  Interaction between virus and host proteins is a critical event through which the 
virus can exploit host cellular processes.  In this study, the interaction between host DEAD-box 
RNA helicase (DDX5) and an RNA-dependent RNA polymerase of HCV (NS5B), will be 
characterized using molecular biology techniques and structural analysis.  
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CHAPTER 21 
 
Expression, Purification and Preliminary 
Crystallographic Analysis of Recombinant 
Human DEAD-Box Polypeptide 5 
 
 
 
 
 
 
 
                                                 
1
This chapter is an expanded version of the manuscript published as Choi, Y. W., Dutta, S., Fielding, B. C., and Tan, 
Y. J. (2010) Expression, purification and preliminary crystallographic analysis of recombinant human DEAD-box 
polypeptide 5, Acta Crystallogr Sect F Struct Biol Cryst Commun 66, 192-194. 
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2.1 Abstract 
The DEAD-box RNA helicase, DDX5, is involved in many aspects of RNA processing and has 
been implicated in a number of cellular processes involving alteration of RNA secondary 
structure.  DDX5 was shown to bind NS5B of Hepatitis C virus (HCV), an RNA-dependent RNA 
polymerase.  We proceeded to characterize this interaction between DDX5 and HCV NS5B by 
constructing deletion mutants of DDX5 for interaction, expression and crystallisation studies.  
Using over-expressed protein in mammalian cells, two interaction sites with NS5B have been 
identified in DDX5 through co-immunoprecipitation, one in the N-terminal region of amino acids 
1 to 384 and the other in the C-terminal region of amino acids 387 to 614.  Full-length and 
different fragments of DDX5 were expressed in bacterial cells and purified under different lysis 
buffer conditions.  DDX5 was found to be less soluble when purified in low salt buffer and low 
induction temperature improved protein yield.  In general, fragments encompassing the C-
terminal end of DDX5 showed signs of degradation after purification.  The N-terminal region of 
DDX5 which contains the conserved domain 1 of the DEAD-box helicases was cloned and 
successfully expressed in Escherichia coli.  In this chapter, the purification and crystallisation 
conditions are presented. 
2.2 Introduction 
RNA helicases are involved in all aspects of RNA metabolism.  They are ATPases with RNA 
binding and unwinding activities, are involved in transcription, pre-mRNA splicing, ribosome 
biogenesis, mRNA nuclear export, translation initiation and degradation of mRNA (Cordin, 
Banroques et al. 2006; Linder 2006).  DDX5 (also known as p68) was first discovered due to its 
cross-reactivity with a monoclonal antibody of the large T antigen of simian virus 40 (Lane and 
Hoeffler 1980).  Subsequent analysis of the DNA sequence of DDX5 revealed an extensive 
homology with translation initiation factor eIF-4A.  The molecular similarity of DDX5 with both 
the large T antigen and eIF-4A, an ATP-dependent DNA helicase and an ATP-dependent RNA 
helicase, respectively, implied that DDX5 may function as an RNA or DNA helicase (Ford, Anton 
et al. 1988).  DDX5 belongs to the DEAD-box family of proteins named after their conserved 
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amino acid sequence Asp-Glu-Ala-Asp (D-E-A-D) (Linder, Lasko et al. 1989).  Based on their 
conserved sequence motifs, they are classified under superfamily 2 (SF2) of the helicases 
(Gorbalenya and Koonin 1993).  The DEAD-box family of helicases is characterized by the 
unique Q motif as well as 8 other conserved motifs (Tanner, Cordin et al. 2003). The motifs Q, I 
(Walker A, phosphate-bind P-loop), Ia, Ib, II (Walker B, DExD-box) and III form Domain 1 while 
motifs IV, V and VI form domain 2 (Tanner, Cordin et al. 2003; Cordin, Banroques et al. 2006).  
DDX5 is implicated in a wide range of biological processes, with early studies reporting 
its possible involvement in the regulation of differentiation/maturation of different animal and 
human cells (Abdelhaleem 2005).  Later, it was shown to bind, unwind and rearrange RNA 
secondary structures (Rossler, Straka et al. 2001) and it was also found to be crucial in the 
processing, alternate splicing and degradation of mRNA (Abdelhaleem 2005; Fuller-Pace 2006).  
DDX5 acts as a transcriptional co-regulator to hormone receptors and transcription factors of 
differentiation, transcriptional initiation and mRNA decay (Abdelhaleem 2005; Fuller-Pace and 
Ali 2008).  DDX5 is also a transcriptional co-activator of estrogen receptor (Endoh, Maruyama et 
al. 1999), tumour suppressor p53 (Bates, Nicol et al. 2005), β-catenin (Shin, Rossow et al. 
2007), MyoD (Caretti, Schiltz et al. 2006) and androgen receptor (Clark, Coulson et al. 2008). 
HCV NS5B protein, an RNA-dependent RNA-polymerase crucial to virus replication, was 
found to interact with DDX5, implicating it as a cellular factor involved in HCV replication (Goh, 
Tan et al. 2004).  Overexpression of NS5B results in the redistribution of endogenous p68 from 
the nucleus to the cytoplasm, which may be important for enhancement of viral replication, 
depletion of endogenous DDX5 and associated reduction in the transcription of negative-strand 
HCV RNA (Goh, Tan et al. 2004).  Using co-immunoprecipitation and immunofluorescence 
techniques, we also found that HCV core and its helicase NS3 protein also interacted with 
DDX5 (unpublished data). 
The role of DDX5 in viral replication is not well understood, but other DEAD box RNA 
helicases have been shown to play crucial roles in viral replication.  HCV core protein has also 
been found to interact with DEAD box proteins DBX (Mamiya and Worman 1999), DDX3 
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(Owsianka and Patel 1999) and DDX1 (Tingting, Caiyun et al. 2006).  RNA helicases DDX1 and 
DDX3 have both been implicated in the replication of human immunodeficiency virus type 1 
(HIV-1) through interaction with HIV-1 Rev, they enhance Rev-dependent HIV-1RNA nuclear 
export (Fang, Kubota et al. 2004; Yedavalli, Neuveut et al. 2004).  DDX3 is required for HCV 
RNA replication since its core protein expression level was lower in DDX3 knockdown cells and 
JFH1 RNA production was reduced by up to 90% when DDX3 knockdown cells were infected 
(Ariumi, Kuroki et al. 2007).  DDX1 was also reported to enhance viral replication through 
interaction with non-structural protein 14 of coronavirus (Xu, Khadijah et al. 2010). 
The research undertaken by us identified two independent sites of interaction between 
DDX5 and HCV NS5B and herein we report the cloning, expression, purification and preliminary 
X-ray diffraction analysis of the N-terminal of DDX5 from amino acids 1 to 305, spanning 
domain I of the DEAD-box helicase. 
2.3 Materials and Methods 
2.3.1 Molecular Cloning  
2.3.1.1 DDX5 Constructs for GST Fusion Protein Expression 
DDX5 and its deletion mutants were cloned for fusion protein expression in E. coli (Table 2.1).  
The open reading frame encoding human DDX5 was amplified from a spleen cDNA expression 
library (Goh, Tan et al. 2004).  It was cloned into pGEX6p1 (GE Healthcare, USA), an 
expression plasmid with an amino-terminal glutathione S-transferase (GST) fusion partner.  
Subsequent deletion mutants were amplified from this plasmid.  Sequence identity was 
confirmed by DNA sequencing (DNA Core Facility, IMCB, Singapore).  The constructs were first 
transformed into DH5α bacterial cells before plasmid DNAs were extracted and then 
retransformed into BL21-CodonPlus competent cells (Stratagene) for use in protein expression 
studies.   
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Table 2.1: Constructs generated and used for protein expression. DDX5 and its deletion mutants 
were cloned into the pGEX-6p1vector for fusion protein expression in E. coli.   
Designation Vector Insert 
pGEX6p1-DDX5 1-614 pGEX6p1 DDX5 1-614aa 
pGEX6p1-DDX5 1-480 pGEX6p1 DDX5 1-480aa 
pGEX6p1-DDX5 1-305 pGEX6p1 DDX5 1-305aa 
pGEX6p1-DDX5 1-80 pGEX6p1 DDX5 1-80aa 
pGEX6p1-DDX5 43-487 pGEX6p1 DDX5 43-487aa 
pGEX6p1-DDX5 61-614 pGEX6p1 DDX5 61-614aa 
pGEX6p1-DDX5 61-480 pGEX6p1 DDX5 61-480aa 
pGEX6p1-DDX5 61-434 pGEX6p1 DDX5 61-434aa 
pGEX6p1-DDX5 61-305 pGEX6p1 DDX5 61-305aa 
pGEX6p1-DDX5 72-409 pGEX6p1 DDX5 72-409aa 
pGEX6p1-DDX5 80-614 pGEX6p1 DDX5 80-614aa 
pGEX6p1-DDX5 80-480 pGEX6p1 DDX5 80-480aa 
pGEX6p1-DDX5 80-305 pGEX6p1 DDX5 80-305aa 
pGEX6p1-DDX5 132-434 pGEX6p1 DDX5 132-434aa 
pGEX6p1-DDX5 163-411 pGEX6p1 DDX5 163-411aa 
pGEX6p1-DDX5 204-391 pGEX6p1 DDX5 204-391aa 
pGEX6p1-DDX5 306-614 pGEX6p1 DDX5 306-614aa 
pGEX6p1-DDX5 306-480 pGEX6p1 DDX5 306-480aa 
pGEX6p1-DDX5 406-574 pGEX6p1 DDX5 406-574aa 
pGEX6p1-DDX5 480-614 pGEX6p1 DDX5 480-614aa 
pGEX6p1-NS5B  delC21 pGEX6p1 NS5B deleted C-terminal 21aa 
pGEX6p1-NS5B  282-570 pGEX6p1 NS5B 282-570aa 
2.3.1.2 Polymerase Chain Reaction (PCR) 
Amplification of specific gene fragments was performed using the respective primers flanking 
the 3’ and 5’ ends of constructs (APPENDIX 1) in a T3000 Thermocycler (Biometra, USA).  DNA 
template (1 μl) was used in a 50 μl PCR mix containing 1xPCR buffer (Promega, USA), 1 μl 10 
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mM dNTP (New England Biolabs, USA), 1 μl of 10 μM forward and reverse primer and 1.0 U 
Taq DNA polymerase (Roche Diagnostic, USA).  PCR reactions were cycled under the following 
conditions: initial denaturation at 94°C for 2 minutes (min), followed by 30-35 cycles of (i) 94°C 
for 30 seconds (s), (ii) annealing for 20-30 s with annealing temperature determined by the 
primer sets used (APPENDIX 1), (iii) elongation at 72°C for 60 s per 1000 bps and a final 
elongation step at 72°C for 5 min.  
2.3.1.3 Agarose Gel Electrophoresis 
5X DNA loading dye (25% glycerol, Invitrogen, USA) and 0.1% bromophenol blue (Sigma-
Aldrich, USA) was added to DNA samples before being resolved on a 1.25% agarose gel 
(UltraPure™ Agarose, Invitrogen, USA) with 200 ng/ml of ethidium bromide (Bio-Rad) added.  
0.5X TBE buffer (44.5 mM Tris, 44.5 mM boric acid and 1 mM EDTA) was used in a Hoefer HE 
33 mini horizontal submarine unit (Pharmacia Biotech, USA, GE Healthecare) for 
electrophoresis.  Electrophoresis was carried out at 120 volts using power supply EPS 500/400 
(Pharmacia Biotech, USA).  DNA bands were visualised under UV light using GeneFlash 
(Syngene Bio Imaging, UK).  0.5 µg of either 100 bp or 1 kb DNA ladder (New England Biolabs, 
USA) was loaded with the sample for size reference. 
2.3.1.4 DNA Extraction and Gel Purification 
DNA bands corresponding to the expected size was excised from the agarose gel with a sterile 
surgical blade.  DNA was extracted and purified using Qiagen’s Gel Extraction Kit (Qiagen, 
Germany), adhering to the manufacturer’s protocol.  The purified DNA was stored at -20°C. 
2.3.1.5 Restriction Enzyme Digest and Ligation 
BamHI and XhoI restriction endonucleases (New England Biolabs, USA) were used for cloning.  
0.5 μl of each restriction endonuclease was added to a mixture containing 15 μl of DNA sample, 
2 μl of 10X BSA and 2 μl of 10x BamHI buffer.  Digestion was carried out for 3 hours at 37°C in 
a T3000 Thermocycler.  7.5 μl of the digested DNA insert was added to 1 μl of the plasmid 
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vector, 1 μl of 10x T4 DNA ligation buffer (New England Biolabs, USA), and 0.5 μl of T4 DNA 
ligase (New England Biolabs, USA).  Ligation was carried out overnight at 16°C using T3000 
Thermocycler. 
2.3.1.6 Bacterial Transformation 
Ligated DNA products were transformed into 100 µl of chemical competent E. coli strain DH5α 
for plasmid isolation.  Purified and sequence-verified plasmid DNA for protein expression was 
transformed into chemical competent BL21-CodonPlus RIL (Stratagene, USA).  Briefly, DNA 
was added to the bacterial cells and incubated on ice for 30 min before heat shock treatment in 
a 42°C water bath for 45 s.  The transformed cells were recovered with 500 μl LB broth at 37°C 
for 45 min in a water bath (Grant, UK).  The cells were then plated onto LB plates containing 
100 μg/ml ampicillin and incubated at 37°C overnight for selection of clones. 
2.3.1.7 Plasmid DNA Isolation and Purification from Escherichia coli Cells 
Single colonies were picked and inoculated into LB broth containing 100 μg/ml of ampicillin and 
incubated at 37°C overnight with shaking.  QIAprep Spin Miniprep Kit and QIAGEN Plasmid 
Midi Kit (Qiagen, Germany) were used for the isolation of plasmid DNA, following the 
manufacturer’s protocol.  The isolated plasmids were stored at -20°C. 
2.3.1.8 DNA Sequencing 
ABI PRISM BigDye™ Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystem, 
USA) was used for sequencing according to the manufacturer’s protocol, with the appropriate 
primers.  The extension products were then sequenced (Sequence Facility, Institute of 
Molecular and Cell Biology, Singapore).  The published DDX5 and DDX1 sequences were 
obtained from National Center for Biotechnology Information (NCBI) database and analysis of 
the sequences were done using SeqMan II expert sequence analysis software (DNASTAR, 
USA). 
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2.3.1.9 Constructs for Expression and Co-Immunoprecipitation Studies in 
Mammalian Cells 
DDX5 and selected deletion mutants constructed for fusion protein expression were sub-cloned 
into plasmids derived from pXJ40 (Xiao, Davidson et al. 1991) using BamHI and XhoI (New 
England Biolabs, USA) restriction endonuclease.   
Table 2.2: Constructs generated and used in co-immunoprecipitation studies.  DDX5 and its 
deletion mutants were cloned into the pXJ40myc and NS5B was cloned into pXJ40flag vectors used for 
protein expression in mammalian cells.  
Designation Vector Insert 
pXJmyc-DDX5 pXJ40myc DDX5 
pXJmyc-DDX5 1-384 pXJ40myc DDX5 1-384aa 
pXJmyc-DDX5 1-507 pXJ40myc DDX5 1-507aa 
pXJmyc-DDX5 206-614 pXJ40myc DDX5 206-614aa 
pXJmyc-DDX5 206-507 pXJ40myc DDX5 206-507aa 
pXJmyc-GST pXJ40myc GST 
pXJflag-NS5B pXJ40flag NS5B 
2.3.2 Cell Culture and Protein Analysis  
2.3.2.1 Cell Lines and Maintenance 
Huh 7 cells (Human hepatoma, JCRB Cell Bank) were cultured in standard Delbecco’s Minimal 
Eagle’s medium supplemented with 10% foetal calf serum (HyClone Laboratories) and 
antibiotics (penicillin at 10 Units/ml and streptomycin at 100 μg/ml (Sigma)) and were 
maintained at 37°C in 5% carbon dioxide.  Mammalian cells were transfected with 
Lipofectamine™ 2000 Reagent (Invitrogen) according to the manufacturer’s protocol. 
2.3.2.2 Cell Harvesting 
Cells were harvested 24 hours post transfection.  A cell scraper was used to dislodge the 
attached cells into culture medium, the cells were then harvested by centrifugation at 1500 rpm 
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for 5 minutes at 4°C.  The cell pellets were washed twice with phosphate-buffered saline (PBS) 
before 150 µl of RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% NP-40, 0.5% deoxycholic 
acid, 0.005% SDS and 1 mM phenylmethylsulfonyl fluoride (PMSF)) was added.  The lysates 
were transferred to 1.5 ml microfuge tubes and subjected to three freeze-thaw cycles.  The cell 
lysates were centrifuged at 14000 rpm for 20 minutes at 4°C to remove cell debris.  The 
concentration of the cell supernatant was determined for use in Western Blot analysis and co-
immunoprecipitation experiments.   
2.3.2.3 Quantitation of Mammalian Cell Lysate Protein Concentration 
Protein solution (5 μl) was added to 1 ml of Coomassie Plus Protein Assay Reagent (Pierce, 
USA) in a plastic cuvette.  RIPA buffer was used as a reference.  Optical density of the protein 
solution was measured at 595 nm using an Ultraspec II spectrophotometer (LKB Biochrom, 
England), and the protein concentration were obtained by comparison with the standard curve. 
2.3.2.4 Co-Immunoprecipitation 
Using 1.5 ml microcentrifuge tubes, 200 μg of cell lysate was incubated for 1 hr at room 
temperature with 10 μl of ANTI-FLAG M2 affinity gel (Sigma) pre-washed with RIPA buffer.  The 
protein bound agarose gel was washed 4 times with 1 ml RIPA buffer.  The agarose gel was 
spun at 1500 rpm for 3 min between each wash.  5 X SDS loading buffer (0.3 M Tris-HCl, pH 
6.8, 5% SDS, 50% glycerol, 0.1 M DTT and 0.1% bromophenol blue) was added to the washed 
gel.  Bound proteins were eluted from the beads by boiling the samples at 100°C for 5 minutes.  
2.3.2.5 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
denatured proteins according to their molecular weight.  5 X SDS loading buffer (0.3 M Tris-HCl 
pH 6.8, 5% SDS, 50% glycerol, 0.1M DTT and 0.1% bromophenol blue) were added to protein 
samples and boiled for 5 min at 100°C.  The protein samples were resolved on 7.5 –15% SDS-
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PAGE gels, using Mini-PROTEAN® 3 Cell (Bio-Rad).  Electrophoresis was carried out at 20 mA 
per gel using a PowerPac 3000 (Bio-Rad).  Protein ladders used were BenechMarkTM 
Pretasined Ladder (Invitrogen), BenechMarkTM Protein Ladder (Invitrogen) or PageRulerTM 
Unstained Protein Ladder (Fermentas). 
2.3.2.6 Western Blot Analysis 
The cell lysate samples and immunoprecipitated (IP) protein samples were resolved with SDS-
PAGE (see 2.3.2.5), transferred onto Hybond-C nitrocellulose membranes (GE Healthcare) and 
blocked with 5% non-fat milk in PBS with 0.05% Tween-20.  The membranes were then 
incubated with an appropriate primary antibody to detect the protein, followed by the 
corresponding secondary antibody conjugated with horseradish peroxidase to detect the 
membrane bound antibodies (Table 2.3).  The proteins were then visualised with the aid of 
SuperSignal® West Pico Substrate Kit (Pierce).  The chemiluminescent protein signals were 
captured on Amersham Hyperfilm™ (GE Healthcare).  
2.3.3 GST Fusion Protein Expression and Purification 
GST-DDX5 and its deletion mutants for the protein expression were transformed into the E. coli 
strain BL21-CodonPlus RIL (Stratagene, USA) and tested on a small scale of 50 ml cultures 
before certain clones were chosen for larger preparations of 4-7 L cultures.  SDS-PAGE and 
Coomassie staining was used to check for the presence of fusion protein during purification.  
2.3.3.1 Small-Scale GST Fusion Protein Expression  
Bacteria were cultured in Terrific Broth with ampicillin (Sigma) 100 µg/ml and chloramphenicol 
(Fluka, USA) 20 µg/ml at 37°C.  The cultures were grown to an absorbance of about 1 at 600 
nm. The temperature was lowered before 0.2 mM of isopropyl-β-d-thiogalactopyranoside 
(Invitrogen, USA) was added to the cultures for the induction of recombinant protein production 
at 30°C for 3 hours (h) or 16°C for 24h.  The bacterial cells were harvested by centrifugation at 
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4000 rpm at 4°C and the cell pellets were stored at -20°C before processing.  The pellets were 
suspended in 10 ml lysis buffer with complete EDTA-free protease inhibitor (Roche Diagnostics, 
USA), according to manufacturer’s instructions.  The cells were lysed by sonication.  Cell debris 
were removed by centrifugation for 1 hour at 14 000 rpm at 4°C.  The soluble fractions were 
mixed with 100 µl of Gluthione Sepharose 4B (GSH) beads (GE Healthcare, USA), pre-washed 
with lysis buffer.  The mixtures were allowed to bind for 3 hours at 4°C with constant mixing on a 
blood tube rotator.  The protein bound beads were washed four times with lysis buffer to remove 
unbound proteins and resuspended in 1 ml lysis buffer (GST fusion protein bound on GSH 
beads can be used in GST pull-down assay at this stage).  Elution buffer (50 mM Tris-HCl, pH 
9.2 with 3 mg/ml reduced L-glutathione, Sigma) was added to the washed beads to elute bound 
fusion protein for 30 minutes at room temperature.  The first elution was collected after spinning 
down the beads and a second elution was carried out overnight at 4°C.  To cleave the protein 
from GST, C3 protease was added to the first elution and left at 4°C overnight.  A small sample 
was taken at each step of the purification for analysis with SDS-PAGE and Coomassie Blue 
staining. 
 
Table 2.3: Primary and secondary antibodies used in Western blotting.   
Primary Antibody Type Source 
Rabbit Anti c-Myc (A-14) 
(Catalogue number sc-789) 
Polyclonal Santa Cruz Biotechnology 
 
Rabbit Anti-Flag 
(Catalogue number F7425) 
Polyclonal Sigma 
Secondary Antibody   
Goat Anti-Rabbit IGG(FC) HRP 
(Catalogue number 31463) 
Pierce  
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Table 2.4: Different lysis buffers used. 
1.  50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM MgCl2 and 1 mM dithiotreitol (DTT) 
2.  50 mM Tris-HCl, pH 7.4, 150 mM KCl, 1 mM MgCl2 and 1 mM DTT 
3.  50 mM Tris-HCl, pH 7.4, 400 mM NaCl and 0.2 mM DTT 
4.  50 mM Tris-HCl, pH 7.4, 300 mM NaCl and 0.2 mM DTT 
5.  50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10% glycerol, 5 mM MgCl2 and 0.2 mM DTT 
6.  50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10% glycerol, 5 mM MgCl2, 1.5% sarkosyl and 0.2 mM 
DTT 
2.3.3.2 Large-Scale GST Fusion Protein Expression and Purification for 
Crystallisation  
Bacteria were cultured in Terrific Broth with ampicillin (Sigma) 100 µg /ml and chloramphenicol 
(Fluka, USA) 20 µg /ml at 37°C.  The cultures were grown to an absorbance of about 1 at 600 
nm.  The cultures were chilled for 30 minutes while the temperature was lowered before 0.2 mM 
of isopropyl-β-d-thiogalactopyranoside (Invitrogen, USA) was added to the cultures for the 
induction of recombinant protein production.  The bacterial cells were harvested by 
centrifugation at 4000 rpm at 4°C and the cell pellets were stored at -20°C before processing.  
The pellets were later suspended in 40 ml lysis buffer with complete EDTA-free protease 
inhibitor (Roche Diagnostics, USA), according to manufacturer’s instructions.  The cells were 
lysed by sonication.  Cell debris were removed by centrifugation for 1 hour at 14 000 rpm at 
4°C.  The soluble fractions were mixed with 3 ml of Gluthione Sepharose 4B (GSH) beads (GE 
Healthcare, USA), pre-washed with lysis buffer.  The mixtures were allowed to bind for 3h at 
4°C.  The protein-bound beads were washed with lysis buffer to remove unbound proteins and 
resuspended in 40 ml lysis buffer.  3C protease was added to cleave the proteins off the beads, 
leaving the GST tag on the beads, overnight at 4°C.  The cleaved proteins were concentrated 
with Amicon® Ultra-15 Centrifugal Filter Device (Millipore, USA). 
The concentrated proteins were further purified through size exclusion chromatography 
through a Superdex-200 16/60 gel-filtration column (GE Healthcare) pre-equilibrated in gel-
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filtration buffer, using an Äkta basic fast protein liquid chromatography system (GE Healthcare).  
65 fractions of 2 ml were eluted.  Peak fractions were analysed with SDS-PAGE and visualised 
through Coomassie staining to assess protein purity.  The purified protein fractions were 
concentrated with Amicon® Ultra-15 Centrifugal Filter Device (Millipore, USA).  The protein 
concentrations were determined by spectrometry using the molar extinction coefficient at 280 
nm.  The molar extinction coefficients were determined from the protein sequences of the 
proteins using the ProtParam tool.  As a consequence of cleavage, 5 amino acids (GPLGS) 
remained fused to the N-terminus of the purified proteins.  Aliquots of the concentrated protein 
were flash-frozen in liquid nitrogen and stored at −80°C. 
2.3.3.3 Coomassie Blue Staining 
Resolved SDS-PAGE gels were stained in Coomassie solution (10% acetic acid, 45% methanol 
and 0.25% Bio-Rad Coomassie brilliant blue) for 30 min before destaining with several changes 
of destaining solution (10% acetic acid, 45% methanol) over 2 hours or overnight to visualise 
protein bands. 
2.3.3.4 Direct Spectrophotometric Protein Concentration Determination 
The concentration of purified DDX5 1-305 and DDX5 1-480 were determined by direct 
spectrophotometric analysis at a wavelength of 280 nm.  The molar extinction coefficient (78090 
M-1·cm-1) and was calculated based on the amino acid sequence using the PROTPARAM tool 
available on the ExPASyProteomics Server of the Swiss Institute of Bioinformatics 
(http://www.expasy.ch/tools/protparam.html).  
2.3.4 Protein Crystallisation Screens 
Purified proteins were used to set up crystallisation screens.  Screening kits used were Crystal 
ScreenTM, Crystal Screen 2TM, Crystal Screen LiteTM, Grid Screen PEG/LiCl TM, MembFac TM, 
Natrix TM, PEG/Ion Screen TM and PEG/Ion 2 Screen TM from Hamton Research, USA. 
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2.3.4.1 Sitting Drop 
CryschemTM 24-well plates (Hampton Research, USA) were used for the initial screening of 
crystallisation conditions.  Different crystallisation reagents (0.5 ml) were first pipetted into the 
reservoir of each well.  Protein sample (0.5 µl) was pipetted into the post of the reservoir before 
0.5 µl of reagent from the reservoir was added to the drop of protein.  The plate was then sealed 
with Crystal Clear Sealing Tape (Hampton Research,USA).    
2.3.4.2 Hanging Drop  
EasyXtal Tool (Qiagen, USA) 24-well plates were used for refining crystallisation conditions.  
Crystallisation reagents (1 ml) were pipetted into each well.  Protein (1 µl) was pipetted onto the 
bottom side of a screw cap before 1 µl of reagent from a well was added to it.  The cap was 
then screwed onto the well with a drop of protein mixture hanging above the reservoir of 
reagent.  The samples were resolved on 10% SDS-PAGE.  The resolved gel was soaked in a 
fixing solution of 45% methanol and 10% acetic acid for 30 minutes and then placed in NAP100 
Amplify™ (GE Healthcare) solution for 30 minutes.  The gel was then placed on a piece of filter 
paper, covered with cling wrap and dried for 1 hour at 80°C in a Bio-Rad gel drier.  The 
radiolabelled signals were captured on Amersham Hyperfilm™ (GE Healthcare). 
2.4 Results and Discussion 
2.4.1 Mapping the Domain of Interaction of DDX5 with HCV NS5B 
A panel of DDX5 deletion mutants and NS5B cloned into pXJ40 for previous studies were used.  
They were co-transfected into Huh-7 cells for protein expression and interaction studies using 
co-immunoprecipitation and western blot techniques. 
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2.4.1.1 HCV NS5B Interacted with DDX5 and DDX5 Deletion Mutants 
The top panel of Figure 2.1 shows flag-tagged HCV NS5B co-immunoprecipitated with myc-
tagged DDX5 and DDX5 deletion mutants 1-348, 1-507, 206-614, 387-614 and 206-507 in lanes 
1 to 6, but not the negative control (myc-GST) in lane 7.  The middle panel indicates the 
expression of flag-NS5B and the bottom panel the expression of myc-tagged proteins.  It was 
noted that myc-DDX5 206-507 in lane 6 of the bottom panel was larger than its expected size of 
about 33 kDa.  Sequence analysis of the clone revealed that the stop codon was missing and 
the expressed myc-DDX5 206-507 contained some vector protein.  The vector protein is, 
however, not expected to affect the outcome of the co-immunoprecipitation result with NS5B. 
2.4.1.2 NS5B Interacted Independently with Two Sites on DDX5 
Figure 2.2 is an alignment map of myc-DDX5 and its deletion mutants which shows positive 
interaction with flag-NS5B.  From the map, it can be seen that myc-DDX5 1-384 and myc-DDX5 
387-614, which represents two exclusive regions of DDX5, co-immunoprecipitated with flag-
NS5B.  The results indicate that there are two interaction sites in DDX5 where NS5B could bind. 
2.4.2 Cloning of DDX5 Plasmids for GST Fusion Protein Expression in E. 
coli  
DDX5 and a new panel of deletion mutants spanning DDX5 were cloned for GST pull-down 
interaction studies with NS5B to locate the binding sites identified in clones DDX5 1-384 and 
DDX5 387-614 (Figure 2.3).  DDX5 was amplified from a spleen cDNA expression library and 
cloned into pGEX6p1, an expression plasmid with an amino-terminal glutathione S-transferase 
(GST) fusion partner for protein expression in bacterial cells. 
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2.4.3 Expression and Purification of Fusion Protein in a Bacterial System  
2.4.3.1 Expression of GST-DDX5 61-434, GST-DDX5 163-411 GST-DDX5 204-
319 and GST-DDX5132-434 at 30ºC Induction 
Expression of deletion mutants GST-DDX561-434, GST-DDX5 163-411, GST-DDX5 204-319, 
and GST-DDX5132-434 were first tested with cell pellets harvested from 50 ml E. coli cultures 
grown to OD of about 1 at 37ºC, after chilling, it was induced at 30ºC for 3h.  They were lysed 
by sonication in 10 ml of lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM MgCl2 and 1 mM 
DTT).  The supernatant of the lysed cells were mixed with 30 µl of GSH Sepharose 4B and left 
to bind for 3h at 4ºC.  In Figure 2.4A, lane 3, some GST-DDX5 61-434 fusion protein was 
detected at 70 kDa and a co-purified protein at 60 kDa was also bound to GSH Sepharose 4B.  
Very little fusion protein was detected in elution 1, but the co-purified protein was clearly present 
(Figure 2.4A, lane 5).  No cleaved fusion protein was detectable in lane 6, and the co-purified 
protein was not cleaved by 3C protease (Figure 2.4A).  No protein was detected in elution 2.  C3 
protease and GST proteins (Figure 2.4A, lanes 8 and 9) were loaded as input and size 
references for C3 cleaved elution 1 because C3 cleaved fusion protein are detected as a 
smaller protein band and a GST band.  More fusion protein of interest may be in the insoluble 
fraction at between 60 and 70 kDa (Figure 2.4A, lane 1).  GST-DDX5 163-411 and GST-
DDX5132-434 showed no bound fusion protein (Figure 2.4B, lane 3 and Figure 2.4D, lane 3).   
2.4.3.2 Expression of GST-DDX5 61-434, and GST-DDX5132- 434 at 16ºC 
Induction 
To check if a lower induction temperature increases the production and solubility of the fusion 
proteins, GST-DDX5 61-434, and GST-DDX5132-434 were cultured again at 37ºC and induced 
at 16ºC for 24h before purification with the same lysis buffer (50 mM Tris pH 7.4, 150 mM Na Cl, 
1 mM MgCl2 and 1 mM DTT).  In Figure 2.5A, more fusion protein of GST-DDX5 61-434 was 
detected in lane 3 and elution 1 in lane 4.  Three major bands were observed in elution 1 in lane 
4, the top band at about 70 kDa should be GST-DDX5 61-434, the band at 60 kDa was the 
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unknown co-purified protein that was also seen in Figure 2.1A, lane 5, while the third band at 
about 30 kDa may be a truncated product of GST-DDX5 61-434.  In lane 4, the major band at 
about 70 kDa in lane 5 was cleaved by C3 protease to yield a protein band above 40 kDa just 
below the C3 protease and a GST band at about 26 kDa.  The truncated fusion protein was also 
cleaved by C3.  The co-purified protein remains unchanged at 60 kDa.   
 
Figure 2.1: Co-immunoprecipitation of DDX5 deletion mutants with HCV NS5B in co-
transfected Huh-7 cells.Top panel: Flag-NS5B IP with myc-p68 and myc-p68 mutants (lanes 1-6) 
but not with myc-GST (lane 7) detected with monoclonal anti-flag antibody.Middle panel: Flag- 
NS5B detected with rabbit anti-flag antibody.  Bottom panel: Lane 1, myc-DDX5.  Lane 2, myc-
DDX5 1-348. Lane 3, myc-DDX5 1-507, lane 4, myc-DDX5 206-614. Lane 5, myc-DDX5387-614.  
Lane 6, myc-DDX5 206-507. Lane 7, myc-GST.  Detected with rabbit anti-myc antibody. 
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Figure 2.2: Two exclusive DDX5 interaction sites with HCV NS5B.  Co-immunoprecipitation 
results identified non over-lapping regions 1-384 and 387-614 in DDX5, indicating that NS5B can 
interact with either one of the sites. 
In Figure 2.5B, a small amount of GST-DDX5 132-434 was detected in the GSH bound fraction 
and in elution 1 and 2 (lanes 3, 4 and 6).  The fusion protein appeared just below a co-purified 
protein band at 60 kDa (lane 4), and was cleaved by C3 protease in lane 5, but post cleavage 
product was not detected.   
2.4.3.3 Expression of GST-DDX5 43-487 and GST-DDX5 at 30º C Induction 
GST-DDX5 43-487 and GST-DDX5 were cultured and induced at 30ºC for 3h.  A different lysis 
buffer (50 mM Tris-HCl pH 7.4, 150 mM KCl, 1 mM MgCl2 and 1 mM DTT) was used.  In Figure 
2.6A, GSH bound GST-DDX5 43-487 was clearly detected in lane 3 at about 75kDa.  It eluted 
from the GSH beads as a clean band in lane 4 and was cleaved by C3 protease to produce a 
protein band at about 50 kDa and a GST band at about 26 kDa.  More fusion protein of interest 
may be in the insoluble fraction at about 75 kDa in lane 1.  The expression profile of GST-DDX5 
in Figure 2.6B was not very distinct, besides three protein bands observed at 60, 80 and 100 
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kDa, and multiple bands were present between 25-40 kDa in lane 3.  The full length DDX5 may 
not be stable when expressed as a GST fusion protein.    
2.4.3.4 Expression of GST-DDX5 43-487 and GST-DDX5 at 16ºC Induction 
GST-DDX5 43-487 and GST-DDX5 were cultured again and induced at 16ºC for 24h to see if a 
lower induction temperature had any effect on their expression and solubility profiles.  The 
harvested cells were sonicated in10 ml lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM KCl, 1 mM 
MgCl2 and 1 mM DTT).  More GST-DDX5 43-487 was detected in lane 3 of Figure 2.7A, but a 
few smaller protein bands were also detected.  Precipitates were observed after the fusion 
protein was eluted from the GSH beads.  Samples of the precipitates were prepared and loaded 
in lane 8, where a lot of the fusion protein and proteins which maybe its degradation products 
were detected.  Similar observations were made with GST-DDX5 in Figure 2.7B, more fusion 
protein were obtained as GSH bound fusion protein in lane 3, and it was also present in the first 
and second elutions in lanes 5 and 7.  Precipitation of protein occurred after elution from GSH 
and can be seen as multiple bands in lane 8.  
2.4.3.5 Expression and Purification of GST-DDX5 Deletion Mutants Induced 
at 18ºC and Lysed in Buffer with High Salt Concentration 
Lysis buffer conditions were modified to see if a high salt buffer would help in the stability of 
purified GST-DDX5 and GST-DDX5 43-487.  They were cultured at 37ºC to OD600  of about 1, 
chilled and induced at 18ºC with 0.2 mM IPTG for 24h.  The harvested bacterial cells were lysed 
in 10 ml of lysis buffer (50 mM Tris-HCl, pH. 7.4, 400 mM NaCl and 2 mM DTT).  GST-DDX5 
43-487 and GST-DDX5 purified with lysis buffer with 400 mM of NaCl did not precipitate when 
cleaved from GSH beads.  The rest of the deletion mutants were sequentially tested under 
these conditions.  Figure 2.8 shows the expression profile of some of the clones tested.  In 
Figure 2.8A, GST-DDX5 61-305 in lane3 and GST-DDX5 1-305 in lane 6 showed higher yield 
than GST-306-614 in lane 9. 
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Figure 2.3: Map of GST-DDX5 and 19 GST-DDX5 deletion mutants cloned and tested for 
fusion protein expression. 
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Figure 2.4: SDS-PAGE analysis of GST-DDX5 61-434, GST-DDX5 163-411 GST-DDX5 204-319 
and GST-DDX5132-434 purification after induction at 30º C.  A.  GST-DDX561-434. Lane 1, 
insoluble fraction. Lane 2, soluble fraction.  Lane 3, GSH bound fusion protein. Lane 4, soluble 
fraction after binding with GSH. Lane 5, first elution with elution buffer. Lane 6, 3C cleaved first 
elution. Lane 7, second elution. Lane 8, 3C protease loaded as reference.  Lane 9, GST protein 
loaded as reference.  Lane 10, Protein molecular weight standards.  B.  GST-DDX5 163-411. Lane 
1, insoluble fraction. Lane 2, soluble fraction.  Lane 3, GSH bound fusion protein. Lane 4, soluble 
fraction after binding with GSH. Lane 5, first elution with elution buffer. Lane 6, 3C cleaved first 
elution. Lane 7, second elution. Lane 8, 3C protease.  Lane 9, Protein molecular weight standards.  
Lane 10, GST protein. C.  GST-DDX5 204-319.  Lane 1, insoluble fraction. Lane 2, soluble fraction.  
Lane 3, GSH bound fusion protein. Lane 4, first elution with elution buffer. Lane 5, 3C cleaved first 
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elution. Lane 6, second elution. Lane 7, 3C protease.  Lane 8, GST protein. Lane 9, Protein 
molecular weight standards.  D.  GST-DDX5132-434.  Lane 1, insoluble fraction. Lane 2, soluble 
fraction.  Lane 3, GSH bound fusion protein. Lane 4, first elution with elution buffer. Lane 5, 3C 
cleaved first elution. Lane 6, second elution. Lane 7, 3C protease.  Lane 8, Protein molecular 
weight standards.  Lane 9, GST protein.  
 
 
 
 
 
 
 
 
Figure 2.5. SDS-PAGE of GST-DDX5 61-434, and GST-DDX5 132-434 purification after 
induction at 16ºC.  A.  GST-DDX5 61-434. Lane 1, insoluble fraction. Lane 2, soluble fraction.  
Lane 3, GSH bound fusion protein. Lane 4, first elution with elution buffer. Lane 5, 3C cleaved first 
elution. Lane 6, second elution. Lane 7, 3C protease.  Lane 8, GST protein. Lane 9, protein 
molecular weight standards.  B.  GST-DDX5132-434.  Lane 1, insoluble fraction. Lane 2, soluble 
fraction.  Lane 3, GSH bound fusion protein. Lane 4, first elution with elution buffer. Lane 5, 3C 
cleaved first elution. Lane 6, second elution. Lane 7, 3C protease.  Lane 8, protein molecular 
weight standards.  Lane 9, GST protein. 
In Figure 2.8B, GST-DDX5 80-480 and GST-DDX5 80-614 proteins appeared to be largely 
insoluble, as strong protein band seen at about 70 kDa in the total lysates in lanes 1 and 3, 
which contained the soluble and insoluble proteins, were barely visible in the supernatants in 
lanes 2 and 5, where only soluble proteins were left after centrifugation.  GST-DDX5 80-305 
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was seen as a strong band at about 50 kDa in lane 10.  In Figure 2.8C, GST-DDX5 61-408, 
GST-DDX5306-480 and GST-DDX5 1-480 can been seen in lanes 3, 6 and 9 at about 70, 50 
and 80 kDa, respectively.  Figure 2.8D shows that GST-DDX5 72-409 either did not express 
fully or may have degraded because the protein band detected at about 50 kDa in lane 3 was 
smaller than the expected size of about 63 kDa.  GST-DDX5 406-574 was not purified in lane 9, 
where only multiple protein bands could be seen.  C3 protease and GST proteins were seen in 
lanes 4 and 10 at right above 40 kDa and about 25 kDa.  It was observed that some clones 
expressing the C-terminal of DDX5 produced purified proteins smaller than their expected 
molecular weight.  Examples of such observations are shown in Figure 2.9, in lanes 1 and 2, 
GST-DDX5 480-614 and GST-DDX5 61-614 showed signs of degradation with multiple bands 
smaller than their expected sizes of about 40.7 kDa and 86.8 kDa respectively when analysed 
on SDS-PAGE. 
 
Figure 2.6: SDS-PAGE of GST-DDX5 43-487, and GST-DDX5 purification after induction at 
30º C.  A.  GST-DDX5 43-487. Lane 1, insoluble fraction. Lane 2, soluble fraction.  Lane 3, GSH 
bound fusion protein. Lane 4, first elution with elution buffer. Lane 5, 3C cleaved first elution. Lane 
6, second elution. Lane 7, 3C protease.  Lane 8, GST protein. Lane 9, protein molecular weight 
standards.  B.  GST-DDX5.  Lane 1, insoluble fraction. Lane 2, soluble fraction.  Lane 3, GSH 
bound fusion protein. Lane 4, first elution with elution buffer. Lane 5, 3C cleaved first elution. Lane 
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6, second elution. Lane 7, 3C protease.  Lane 8, protein molecular weight standards.  Lane 9, GST 
protein.    
 
 
Figure 2.7: SDS-PAGE of GST-DDX5 43-487, and GST-DDX5 purification after induction at 
16º C.  A.  GST-DDX5 43-487. Lane 1, insoluble fraction. Lane 2, soluble fraction.  Lane 3, GSH 
bound fusion protein. Lane 4, soluble fraction after binding with GSH. Lane 5, first elution with 
elution buffer. Lane 6, 3C cleaved first elution. Lane 7, second elution. Lane 8, precipitated protein.  
Lane 9, GST protein.  Lane 10, protein molecular weight standards.  B.  GST-DDX5.  Lane 1, 
insoluble fraction. Lane 2, soluble fraction.  Lane 3, GSH bound fusion protein. Lane 4, soluble 
fraction after binding with GSH. Lane 5, first elution with elution buffer. Lane 6, 3C cleaved first 
elution. Lane 7, second elution. Lane 8, precipitated protein.  Lane 9, protein molecular weight 
standards. Lane 10, GST protein.   
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Figure 2.8: SDS-PAGE of GST-DDX5 deletion mutants purified in high salt buffer.  A. 
Expression of GST-DDX5 61-305, GST-DDX5 1-305 and GST-DDX5 306-614.  Lane 1, Total 
lysate of GST-DDX5 61-305.  Lane 2, Supernatant of GST-DDX5 61-305.  Lane 3, GST-DDX5 61-
305.  Lane 4, Total lysate of GST-DDX5 1-305. Lane 5, Supernatant of GST-DDX5 1-305. Lane 6, 
GST-DDX5 1-305. Lane 7, Total lysate of GST-DDX5 306-614.  Lane 8, Supernatant of GST-
DDX5 306-614.  Lane 9, GST-DDX5 306-614.  Lane 10, protein molecular weight standards.  B.  
Expression of GST-DDX5 80-480, GST-DDX5 80-614 and GST-DDX5 80-305.  Lane 1, Total 
lysate of GST-DDX5 80-480.  Lane 2, Supernatant of GST-DDX5 80-480.  Lane 3, GST-DDX5 80-
480.  Lane 4, Total lysate of GST-DDX5 80-614. Lane 5, Supernatant of GST-DDX5 80-614. Lane 
6, GST-DDX5 80-614. Lane 7, Total lysate of GST-DDX5 80-305.  Lane 8, Supernatant of GST-
DDX5 80-305.  Lane 9, GST-DDX5 80-305.  Lane 10, protein molecular weight standards.  C.   
Expression of GST-DDX5 61-480, GST-DDX5 306-480 and GST-DDX5 1-480.  Lane 1, Total 
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lysate of GST-DDX5 61-480.  Lane 2, Supernatant of GST-DDX5 61-480.  Lane 3, GST-DDX5 61-
480.  Lane 4, Total lysate of GST-DDX5 306-480. Lane 5, Supernatant of GST-DDX5 306-480. 
Lane 6, GST-DDX5 306-480. Lane 7, Total lysate of GST-DDX5 1-480.  Lane 8, Supernatant of 
GST-DDX5 1-480.  Lane 9, GST-DDX5 1-480.  Lane 10, protein molecular weight standards.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: SDS-PAGE of GST-DDX5 480-614, and GST-DDX5 61-614 showing GSH-bound 
proteins that were smaller than their expected molecular weight.  Lane 1, GSH bound GST-
DDX5 480-614.  Lane 2, GSH bound GST-DDX5 61-614.  Lane 3, protein molecular weight 
standards.  
2.4.3.6 Expression and Purification of HCV GST-NS5BdelC21 and GST-
NS5B 282-570 
Different expression and lysis buffer conditions were tested for expression of HCV GST-NS5B 
with the last 21 amino acid deleted form the C-terminal and GST-NS5B282-570.  These were 
first induced overnight at 16ºC and processed in lysis buffer with 50 mM Tris-HCl, pH 7.4, 400 
mM NaCl and 2 mM DTT.  As multiple bands of degradation products were seen, another lysis 
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buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10% glycerol 5 mM MgCl2 and 2 mM DTT) was 
tested, followed by changes in induction temperatures and the length of induction time.  
Sarkosyl was also added to the lysis buffer to improve solubility of the proteins.  Although the 
use of sarkosyl improved the yield of the proteins, it did not help with the stability of the cleaved 
products.    
2.4.4 Large-Scale Protein Purification  
Cultures of 4-8 liters of Clones GST-DDX5, GST-DDX5 43-487, GST-DDX5- 1-305, GST-DDX5 
1-480 and GST-1-80 were grown for purification of proteins for crystal trials.  HCV NS5BdelC21 
and NS5B 282-570 were also purified.  
2.4.4.1 Purification of DDX5 
Induction at 16ºC for 24h.  Lysis buffer (50 mM Tris-HCl, pH 7.4, 400 mM NaCl, 2 mM DTT), 
gel-filtration buffer (10 mM Tris-HCl, pH 7.4, 400 mM NaCl, 2 mM DTT).  Two major bands were 
observed at 35 and 50 kDa, both were smaller than the expected full length DDX5 at 68 kDa 
(Figure 2.10). 
 
 
 
 
 
 
 
 
Figure 2.10: SDS-PAGE of DDX5 purification.  Gel-filtration fractions.  Lanes 1-9, gel-filtration 
fractions 35-44.  Lane 10, protein molecular weight standards. 
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2.4.4.2 Purification of DDX5 43-487 
Induction proceeded at 16ºC for 24h.  Lysis buffer (50 mM Tris-HCl, pH 7.4, 400 mM NaCl, 2 
mM DTT), gel-filtration buffer (10 mM Tris-HCl, pH 7.4, 400 mM NaCl, 2 mM DTT).  A major 
protein band was observed at 50 kDa (Figure 2.11). 
 
 
 
 
 
 
 
Figure 2.11: SDS-PAGE of DDX5 43-487 purification.  Lanes 1-10, Gel-filtration fractions 35-44. 
Lane 11, protein molecular weight standards.  
 
2.4.4.3 Purification of DDX5 1-305 
Induction was at 18ºC for 24h.  Lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10% 
glycerol, 5 mM MgCl2, 2 mM DTT), gel-filtration buffer (25 mM Tris-HCl, pH 7.4, 300 mM NaCl, 
10% glycerol, 5 mM MgCl2, 2 mM DTT).  A major band observed at 35 kDa (Figure 2.12). 
2.4.4.4 Purification of DDX5 1-480 
Induction occurred at 18ºC for 24h.  Lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10% 
glycerol, 5 mM MgCl2, 2 mM DTT), gel-filtration buffer (25 mM Tris-HCl, pH 7.4, 300 mM NaCl, 
10% glycerol, 5 mM MgCl2, 2 mM DTT).  One major band was observed at 50 kDa (Figure 2.13).  
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Figure 2.12:. SDS-PAGE of DDX5 1-305 purification.  Gel-filtration fractions.  Lanes 1-9, Gel-
filtration fractions 31-39. Lane 10, protein molecular weight standards.  
 
 
 
 
 
 
 
 
Figure 2.13: SDS-PAGE of DDX5 1-480 purification.  Gel-filtration fractions.  Lanes 1-9, Gel-
filtration fractions 35-43. Lane 10, protein molecular weight standards.  
2.4.4.5 Purification of DDX5 1-80 
Induction was at 18ºC for 24h.  Lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 5% 
glycerol, 5 mM MgCl2, 2 mM DTT), gel-filtration buffer (25 mM Tris-HCl, pH 7.4, 300 mM NaCl, 
10% glycerol, 5 mM MgCl2, 2 mM DTT).  A smeared band observed at about 10-12 kDa (Figure 
2.14). 
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Figure 2.14.  SDS-PAGE of DDX5 1-80 purification.  Gel-filtration fractions. Lanes 1-6, gel-
filtration fractions 57-62. Lane 7, protein molecular weight standards.  
2.4.4.6 Purification of DDX5 61-305 
Induction was at 18ºC for 24h.  Lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 5% 
glycerol, 5 mM MgCl2, 2 mM DTT), gel-filtration buffer (25 mM Tris-HCl, pH 7.4, 300 mM NaCl, 
10% glycerol, 5 mM MgCl2, 2 mM DTT) (Figure 2.15).  
 
 
 
 
 
 
 
Figure 2.15: SDS-PAGE of DDX5 61-305 purification.  Gel-filtration fractions.  Lanes 1-9, gel-
filtration fractions 39-47. Lane 7, protein molecular weight standards.  
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2.4.4.7 Purification of HCV NS5BdelC21 
Induction at 18º C for 24h.   Lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 2 mM DTT), 
gel-filtration buffer (10 mM Tris-HCl, pH 7.4, 300 mM NaCl, 2 mM DTT).  NS5BdelC21 was 
detected at 60 kDa (Figure 2.16).    
 
 
 
 
 
 
Figure 2.16: SDS-PAGE of HCV NS5BdelC21 purification.  Gel-filtration fractions.  Lanes 1-7, 
gel-filtration fractions 22-28. Lane 8, protein molecular weight standards. 
2.4.4.8 Purification of HCV NS5B 282-570  
Induction at 16ºC for 24h.  Lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10% glycerol, 5 
mM MgCl2, 2 mM DTT), gel-filtration buffer (25 mM Tris-HCl, p. 7.4, 300 mM NaCl, 10% glycerol, 
5 mM MgCl2, 2 mM DTT).  NS5B 282-570 was detected as multiple bands below 30 kDa (Figure 
2.17).     
2.4.5 Crystal Screens  
Crystal trials of purified DDX5, DDX5 43-487, DDX5 1-305, DDX5 1-480 and DDX5 1-80 were 
set up at various concentrations with commercial crystal screening kits from Hampton Research 
in 24-well plates.   
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Figure 2.17: SDS-PAGE of HCV NS5B 282-570 purification.  Gel-filtration fractions.  Lanes 1-8, 
gel-filtration fractions 36-47. Lane 8, protein molecular weight standards.  
2.4.5.1 Co-Crystallisation  
At a molar ratio of about 1:3, 12.86 mg/ml of NS5BdelC21 were mixed with 34.43 mg/ml of 
DDX5 43-487 and prepared for a co-crystallisation trial with commercial crystal screening kits 
from Hampton Research in 24 well plates.  No crystal grew in these conditions. 
2.4.5.2 Refinement of Crystal Screens 
When crystal growth was observed in certain chemical conditions, new trays were set up to 
screen around the conditions, with a range of adjustments made to the initial growth conditions, 
in an effort to grow better crystals.  
2.4.5.3 Refinement of DDX5 Screens 
Grid screens with 30% glycerol, 0.05-0.20 M sodium formate, pH 6.60, 7.02, 7.2 7.59 and 5-30% 
polyethylene glycol (PEG) 3550 were set up with 9.24 mg/ml DDX5. 
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PEG3350 Sodium formate (M)  pH  # PEG3350 Sodium formate (M) pH  
5% 0.05 6.60  5% 0.10 6.60 
5% 0.05 7.02  5% 0.10 7.02 
5% 0.05 7.20  5% 0.10 7.20 
5% 0.05 7.59  5% 0.10 7.59 
10% 0.05 6.60  10% 0.10 6.60 
10% 0.05 7.02  10% 0.10 7.02 
10% 0.05 7.20  10% 0.10 7.20 
10% 0.05 7.59  10% 0.10 7.59 
15% 0.05 6.60  15% 0.10 6.60 
15% 0.05 7.02  15% 0.10 7.02 
15% 0.05 7.20  15% 0.10 7.20 
15% 0.05 7.59  15% 0.10 7.59 
20% 0.05 6.60  20% 0.10 6.60 
20% 0.05 7.02  20% 0.10 7.02 
20% 0.05 7.20  20% 0.10 7.20 
20% 0.05 7.59  20% 0.10 7.59 
25% 0.05 6.60  25% 0.10 6.60 
25% 0.05 7.02  25% 0.10 7.02 
25% 0.05 7.20  25% 0.10 7.20 
25% 0.05 7.59  25% 0.10 7.59 
30% 0.05 6.60  30% 0.10 6.60 
30% 0.05 7.02  30% 0.10 7.02 
30% 0.05 7.20  30% 0.10 7.20 
30% 0.05 7.59  30% 0.10 7.59 
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PEG3350 Sodium formate  pH  # PEG3350 Sodium formate  pH  
5% 0.15 6.60  5% 0.20 6.60 
5% 0.15 7.02  5% 0.20 7.02 
5% 0.15 7.20  5% 0.20 7.20 
5% 0.15 7.59  5% 0.20 7.59 
10% 0.15 6.60  10% 0.20 6.60 
10% 0.15 7.02  10% 0.20 7.02 
10% 0.15 7.20  10% 0.20 7.20 
10% 0.15 7.59  10% 0.20 7.59 
15% 0.15 6.60  15% 0.20 6.60 
15% 0.15 7.02  15% 0.20 7.02 
15% 0.15 7.20  15% 0.20 7.20 
15% 0.15 7.59  15% 0.20 7.59 
20% 0.15 6.60  20% 0.20 6.60 
20% 0.15 7.02  20% 0.20 7.02 
20% 0.15 7.20  20% 0.20 7.20 
20% 0.15 7.59  20% 0.20 7.59 
25% 0.15 6.60  25% 0.20 6.60 
25% 0.15 7.02  25% 0.20 7.02 
25% 0.15 7.20  25% 0.20 7.20 
25% 0.15 7.59  25% 0.20 7.59 
30% 0.15 6.60  30% 0.20 6.60 
30% 0.15 7.02  30% 0.20 7.02 
30% 0.15 7.20  30% 0.20 7.20 
30% 0.15 7.59  30% 0.20 7.59 
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Screening conditions were further narrowed to a screen with 30% glycerol, 0.02-0.08 M 
sodium formate, pH 7.59 and 1-6% PEG 3550 with 9.24 mg/ml DDX5.  Crystals picked from this 
tray diffracted poorly when tested. 
 
PEG3350 Sodium formate (M) pH  # PEG3350 Sodium formate (M) pH  
1% 0.02 7.59  4% 0.02 7.59 
1% 0.04 7.59  4% 0.04 7.59 
1% 0.06 7.59  4% 0.06 7.59 
1% 0.08 7.59  4% 0.08 7.59 
2% 0.02 7.59  5% 0.02 7.59 
2% 0.04 7.59  5% 0.04 7.59 
2% 0.06 7.59  5% 0.06 7.59 
2% 0.08 7.59  5% 0.08 7.59 
3% 0.02 7.59  6% 0.02 7.59 
3% 0.04 7.59  6% 0.04 7.59 
3% 0.06 7.59  6% 0.06 7.59 
3% 0.08 7.59  6% 0.08 7.59 
2.4.5.4 Refinement of DDX5 43-487 Screen 
Grid screen with 0.05 M bicine pH 9.0, 0.05-0.30 M LiCl2 and 5-20% PEG 6000 were set up with 
10 mg/ml DDX5 43-487.  No crystals were obtained using these conditions. 
 
PEG6000 0.05 M Bicine/LiCl2 (M), pH 9.0 # PEG6000 0.05 M Bicine/LiCl2 (M), pH 9.0 
5% 0.05  15% 0.05 
5% 0.01  15% 0.01 
5% 0.15  15% 0.15 
5% 0.20  15% 0.20 
5% 0.25  15% 0.25 
5% 0.30  15% 0.30 
 
 
 
 
  Preliminary Crystallographic Analysis  
55 
 
10% 0.05  20% 0.05 
10% 0.01  20% 0.01 
10% 0.15  20% 0.15 
10% 0.20  20% 0.20 
10% 0.25  20% 0.25 
10% 0.30  20% 0.30 
 
2.4.5.5 Refinement of DDX5 1-305 Screen 
Grid screens with 20% PEG 3350, 0.1 M Bis-Tris pH 6.5 and 1-6% Tacsimate, pH 4.00-7.00, 
20% PEG MW3350 and 2-12% Tacsimate pH 7.00, and 0.2 M NaCl and 5-30% PEG 3350 
were set up with 11 mg/ml of DDX5 1-305.  Crystals were collected from wells with, 0.1 M Bis 
Tris pH 6.5, 2% Tacsimate, pH 4.0 and 20% PEG 3350.  The crystals were soaked in 
cryosolution containing 0.1 M Bis Tris pH 6.5, 2% Tacsimate, pH 4.0, 20% PEG 3350 and 25% 
glycerol and flash-cooled in liquid nitrogen.  Dr Sujit Datta collected native data sets using a 
Quantum CCD image plate on beamline13B1 at the National Synchrotron Radiation Research 
Center (NSRRC) in Taiwan, and solved the structure of DDX5 1-305 (Figure 2.18).    
 
 
 
 
 
 
 
 
Figure 2.18: Crystals of DDX5 1-305 
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2.4.5.6 Refinement of DDX5 1-480 Screen 
Grid screens with 20% PEG MW3350, 0.05-4% Triptone and  0.05-0.20 M HEPES pH 7.30 and 
two with 1% Triptone, 1-30% PEG MW3350 and 0.05-0.20 M HEPES pH 7.30 were set up with 
10 mg/ml DDX5 1-480.  No new crystal was obtained with these conditions.  
2.5 Conclusion 
DDX5 and its deletion mutants were cloned and expressed in E. coli BL21-CodonPlus RIL.  
DDX5 was not stable when processed in low salt buffer which led to precipitation of the protein.  
Even in high salt buffer conditions, efforts to purify a homogeneous full length DDX5 failed.  It 
was noted that the C-terminal of DDX5 was prone to degradation and resulted in truncated 
proteins.  The N-terminal of DDX5 1-305 was successfully purified to homogeneity and crystals 
first appeared within 2 weeks of incubation.  Native data were collected from a single crystal of 
DDX5 1-305 grown in 0.1 M Bis-Tris pH 6.5, 2% (v/v) Tacsimate, pH 4.0 and 20% (w/v) PEG 
MW3350.  The crystals grew to dimensions of 0.15 x 0.05 x 0.05 mm (Figure 2.18).  The 
structural information gained from this crystal will be used in further studies on the interaction 
between DDX5 (the host RNA helicase) and HCV NS5B (viral RNA dependent RNA polymerase.  
 
 
 
 
  Human DDX5 Interaction with Hepatitis C Virus NS5B 
 
57 
 
 
 
 
 
CHAPTER 3
1
 
 
Structural and Functional Characterization of 
Human DDX5 and Its Interaction with NS5B of 
Hepatitis C Virus 
 
 
 
 
 
 
 
                                                 
1This chapter is an expanded version of the manuscript submitted for publication as Sujit Dutta, Yook-Wah Choi, 
Masayo Kotaka, Burtram C. Fielding, Yee-Joo Tan. Structural and functional characterization of human DDX5 and its 
interaction with NS5B of hepatitis C virus. 
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3.1 Abstract 
RNA helicases of the DEAD-box (Asp-Glu-Ala-Asp) family of proteins are involved in many 
aspects of RNA metabolism from transcription to RNA decay.  They are ATPases that have 
many functions, including nuclear and mitochondrial splicing.  They contain two conserved 
domains responsible for RNA binding and ATP hydrolysis.  Human DEAD-box helicase DDX5 
has also been implicated in a number of processes including transcription, RNA splicing and 
RNA decay.  Previous studies show that full-length DDX5 can bind to NS5B of Hepatitis C virus 
(HCV).  In this chapter, we report that there are two independent NS5B binding sites in DDX5, 
one located at the N-terminus and another at the C-terminus.  The N-terminal fragment of 
DDX5, DDX5-1-305, was crystallized and the structure of domain I of DDX5 shows typical 
features found in the structures of other DEAD-box helicases.  In front of domain I is the highly 
variable N-terminal region (NTR) of unknown function, but greatly disordered with only part of 
the NTR region (51-78) observable.  This region forms an extensive loop and supplements the 
core with an additional -helix.  Co-immunoprecipitation experiments revealed that the NTR of 
DDX5 1-305 auto-inhibits its interaction with NS5B.  Interestingly, the -helix in NTR is essential 
for this auto-inhibition and seems to mediate the interaction between the highly flexible 1-60 
residues in NTR and NS5B binding site in DDX5 1-305, presumably located within residues 79-
305.  Furthermore, co-immunoprecipitation experiments showed that DDX5 can also interact 
with other HCV proteins besides NS5B. 
3.2 Introduction 
Hepatitis C is an infectious disease affecting an estimated 150-200 million people worldwide.  
Infection is caused by the HCV, which can often lead to cirrhosis, steatosis, and hepatocellular 
carcinoma.  HCV is an enveloped, single stranded positive-sense RNA virus in the family 
Flaviviridae (Rosenberg 2001).  The viral genome is encoded by 3 structural proteins (core and 
envelope proteins, E1 and E2) and 7 non-structural proteins (p7, NS2, NS3, NS4A, NS4B, 
NS5A and NS5B). NS3, a serine protease and an RNA helicase, along with NS5B, an RNA-
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dependent RNA polymerase (RdRP), are key enzymes required for HCV replication and 
therefore common targets for antiviral agents.  Viral replication requires interaction between 
RNA, viral and host proteins (Rosenberg 2001).  NS5B has been shown to interact with a 
growing number of host proteins, including eukaryotic initiation factor 4AII (Kyono, Miyashiro et 
al. 2002), cellular vesicle membrane transport protein VAP-33 (Tu, Gao et al. 1999), nucleolar 
phosphoprotein nucleolin (Ford, Anton et al. 1988) and the DEAD-box (Asp-Glu-Ala-Asp) RNA 
helicase DDX5 (Goh, Tan et al. 2004). 
DDX5, also referred to as p68, is a nuclear prototypic member of the DEAD-box family of 
proteins.  The DEAD-box family belongs to helicase superfamily II (SFII), which includes DEAH-
box and Snf2 families (Gorbalenya, Koonin et al. 1989; Linder, Lasko et al. 1989; Cordin, 
Banroques et al. 2006; Fuller-Pace 2006; Linder 2006).  DEAD-box helicases share 9 
conserved motifs that are clustered in a central region and possess highly variable amino- and 
carboxyl-terminals.  The central region of DEAD-box helicases can be organized into two 
domains; domain I consists of motifs Q, I (Walker A), II (Walker B, DEAD box), Ia, Ib, III and 
domain II consists of motifs IV, V, and VI. Motif Q, unique to DEAD-box helicases, along with 
motif I and II form the nucleotide binding site.  Motif III has been implicated in linking ATP 
binding and hydrolysis with the helical activity.  The remaining motifs are involved in RNA 
binding.  The variable N- and C-terminal regions are involved in interacting with transcription 
factors and play an important role in transcriptional regulation. 
DDX5 was first identified by its immunological cross-reactivity to a monoclonal antibody 
to the large T antigen of simian virus 40 (Lane and Hoeffler 1980).  Co-purification of DDX5 with 
spliceosome initially suggested a role in RNA splicing and this was subsequently confirmed 
when DDX5 was shown to be an essential splicing protein acting at the U1 snRNA-5’ splice site 
(Liu 2002). DDX5 has also been shown to be involved in RNA export, ribosome assembly, 
translation and RNA degradation (Rossler, Straka et al. 2001; Abdelhaleem 2005; Fuller-Pace 
2006).  However, there is a growing body of evidence suggesting DDX5 may have an additional 
role as a co-transcriptional co-activator.  Current indications suggest that DDX5 is a 
transcriptional co-activator of estrogen receptor (Endoh, Maruyama et al. 1999), tumour 
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suppressor p53 (Bates, Nicol et al. 2005), -catenin (Shin, Rossow et al. 2007), MyoD (Caretti, 
Schiltz et al. 2006) and recently androgen receptor (Clark, Coulson et al. 2008) . 
DDX5 has been shown to interact with HCV NS5B suggesting it may play an important 
role in viral replication despite the presence of the viral helicase, NS3 (Goh, Tan et al. 2004).  
Overexpression of NS5B has been shown to result in the redistribution of DDX5 from the 
nucleus to the cytoplasm presumably to enhance HCV replication.  Furthermore, depletion of 
endogenous DDX5 correlated with a reduction in the transcription of negative-strand HCV RNA 
(Goh, Tan et al. 2004).  In addition, single nucleotide polymorphisms (SNPs) in the DDX5 gene 
have been shown to be significantly associated with increased risk of advanced fibrosis in HCV 
patients (Huang, Shiffman et al. 2006). 
In order to gain a better understanding into the mechanism of interaction between DDX5 
and NS5B, we have determined the crystal structure of domain I of DDX5 (residues 51 to 304).  
The contribution of residues in DDX5 to the interaction with NS5B was also evaluated by using 
site-directed mutagenesis and co-immunoprecipitation experiments.  In addition, co-
immunoprecipitation experiments were used to determine if DDX5 can interact with other HCV 
proteins. 
3.3 Experimental Procedures 
3.3.1 Cloning of Plasmids 
3.3.1.1 Mammalian Expression Constructs 
The open reading frame encoding human DDX5 was amplified from a spleen cDNA expression 
library (Goh, Tan et al. 2004).  DDX5 was cloned into pXJ40myc, a myc-tagged plasmid derived 
from pXJ40 (Xiao, Davidson et al. 1991).  DDX5 deletion and substitution mutants were 
generated by polymerase chain reaction (PCR) (Figure 3.1) and cloned into pXJ40myc for 
transfection and co-immunoprecipitation study in mammalian cells.  HCV proteins core 1-151, 
core 1-173, NS3, NS4B, NS5A and NS5B were amplified form the cDNA of HCV-S1 of 
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genotype 1b (Lim, Khu et al. 2001), and cloned into pXJ40flag, a flag-tagged plasmid derived 
from pXJ40 (Xiao, Davidson et al. 1991).   
3.3.1.2 Glutathione S-Transferase (GST) Fusion Protein Expression 
Constructs 
DDX5 and its deletion mutants were cloned for fusion protein expression in Escherichia coli 
(Chapter 2, Figure 2.3).  It was cloned into pGEX6p1 (GE Healthcare, USA), an expression 
plasmid with an amino-terminal glutathione S-transferase (GST) fusion partner.  The constructs 
were first transformed into DH5α bacterial cells before plasmid DNAs were extracted and then 
retransformed into BL21-CodonPlus competent cells (Stratagene) for protein expression.  The 
sequence identity of all the plasmids cloned was confirmed by DNA sequencing (DNA Core 
Facility, IMCB, Singapore). 
3.3.2 Cell Lines and Maintenance 
COS-7 cells (African green monkey kidney, ATCC) and Huh-7 cells (human hepatoma, JCRB 
Cell Bank) were cultured in standard Dulbecco’s Minimal Eagle’s medium supplemented with 
10% foetal calf serum (HyClone Laboratories) and antibiotics, penicillin at 10 Units/ml and 
streptomycin at 100 μg/ml (Sigma) and were maintained at 37°C in 5% carbon dioxide. 
3.3.3 Transfection and Co-Immunoprecipitation 
Plasmids were transiently transfected into COS-7 or Huh-7 cells plated in 6-cm2 tissue culture 
dishes using Lipofectamine (Invitrogen), according to manufacturer’s instruction.  The cells were 
harvested 24h post-transfection.  A cell scraper was used to dislodge the attached cells into the 
medium; the cells were then harvested by centrifugation at 1500 rpm for 5 min at 4°C.  The cell 
pellets were washed twice with phosphate-buffered saline (PBS) before 150 μl of RIPA buffer 
(50 mM Tris-HCl, 150 mM NaCl, 0.5% NP-40, 0.5% deoxycholic acid, 0.005% SDS and 1 mM 
phenylmethylsulfonyl fluoride (PMSF)) was added.  The lysates were transferred into 1.5 ml 
microfuge tubes and subjected to three cycles of freezing and thawing.  The cell lysates were 
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spun down at 14000 rpm for 20 min at 4°C to remove cell debris.  The concentration of the cell 
supernatant was determined for use in Western blot analysis and co-immunoprecipitation 
experiments.   
 
 
Figure 3.1: Map of myc-DDX5 and its deletion mutants cloned for co-immunoprecipitation 
with NS5B.  Myc-tagged DDX5s covering the different domains of DDX5 designed for co-
immunoprecipitation studies with Flag-tagged NS5B.    
3.3.3.1 Co-Immunoprecipitation Using Unconjugated Protein A-Agarose 
Beads 
For co-immunoprecipitation studies using Huh-7 cells and DDX5, endogenous co-
immunoprecipitation studies done in COS-7 cells, 200 μg of co-transfected or singly-transfected 
cell lysates were first incubated with 2 µg of primary antibody for 1h at room temperature before 
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mixing with 20 μl pre-washed Protein A-Agarose beads (Roche).  The mixtures were left to 
incubate overnight with agitation at 4°C.  The protein-bound beads were then washed 4 times 
with 1 ml RIPA buffer.  The agarose beads were sedimented at 1500 rpm between each wash.  
5X SDS loading buffer (0.3 M Tris-HCl, pH 6.8, 5% SDS, 50% glycerol, 0.1 M dithiotreitol (DTT) 
and 0.1% bromophenol blue) was added to the washed beads.  The bound proteins were eluted 
from the beads by boiling the samples at 100°C for 5 min.  
3.3.3.2 Co-Immunoprecipitation Using Preconjugated ANTI-FLAG® M2 
Affinity Gel 
For protein interaction studies using COS-7 cells, 200 μg of co-transfected cell lysates were 
added to 20 μl pre-washed ANTI-FLAG® M2 affinity gel (Sigma) and incubated at room 
temperature for 1h with agitation.  The protein-bound beads were then washed 4 times with 
immunoprecipitation (IP) buffer.  SDS-PAGE sample loading dye was added to the beads and 
the bound proteins were eluted from the beads by boiling at 100°C for 5 min.  
3.3.4 Quantitation of Mammalian Cell Lysate Protein Concentration 
5 μl protein solution was added to 1 ml Coomassie Plus Protein Assay Reagent (Pierce, USA) 
in a plastic cuvette.  RIPA buffer was used as a reference.  Optical density of the protein 
solution was measured at 595 nm using an Ultraspec II spectrophotometer (LKB Biochrom, 
England), and the cell lysate protein concentration was obtained by comparison with the 
standard curve. 
3.3.5 SDS-PAGE 
SDS-PAGE was used to separate denatured proteins according to their molecular weight.  5X 
SDS-PAGE loading buffer (0.3 M Tris-HCl, pH 6.8, 5% SDS, 50% glycerol, 0.1 M DTT and 0.1% 
bromophenol blue) were added to protein samples and boiled for 5 min at 100°C.  The protein 
samples were resolved on 7.5 –15% SDS-PAGE gels, using Mini-PROTEAN® 3 Cell (Bio-Rad).  
Electrophoresis was carried out at 20 mA per gel using a PowerPac 3000 (Bio-Rad).  Protein 
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ladders used were BenchMarkTM Prestained Ladder (Invitrogen), BenchMarkTM Protein Ladder 
(Invitrogen) or PageRulerTM Unstained Protein Ladder (Fermentas).  
3.3.6 Western Blotting 
SDS sample loading dye was added to transfected cell lysates and the samples were boiled at 
100°C for 5 min.  The cell lysate samples and IP protein samples were resolved using SDS-
PAGE, transferred onto Hybond-C nitrocellulose membranes (GE Healthcare) and blocked with 
5% non-fat milk in PBS with 0.05% Tween-20.  The membranes were then incubated with 
primary antibodies to detect the protein followed by secondary antibodies conjugated with 
horseradish peroxidase to detect the membrane bound antibodies.  The proteins were then 
visualised with the aid of SuperSignal® West Pico Substrate Kit (Pierce).  The 
chemiluminescent protein signals were captured on Amersham Hyperfilm™ (GE Healthcare).  
3.3.7 Expression and Purification for Crystallisation  
The N-terminal domain of DDX5 (residues 1-305) was expressed as a glutathione-S-
transferease (GST) (pGEX6p1, GE Heathcare) fusion protein.  GST-DDX5 (1-305) was 
expressed in Escherichia coli BL21-CodonPlus-RIL (Stratagene).  The bacterial culture was 
grown in Terrific Broth (TB) with ampicillin (Sigma) 100 μg/ml and chloramphenicol (Fluka) 20 
μg/ml at 37°C.  The cultures were grown to an absorbance of 0.8 at OD600 nm.  The temperature 
was lowered to 16°C and 0.2 mM of isopropyl-β-d-thiogalactopyranoside (IPTG) was added to 
the cultures for the induction of recombinant protein production for 24h.  The bacterial cells were 
harvested by centrifugation at 4000 rpm at 4°C and the pellet was stored at -20°C before 
processing.  The pellet was resuspended in lysis buffer (50 mM Tirs-HCl pH 7.4, 300 mM NaCl 
and 0.2 mM DTT) supplemented with complete EDTA-free protease inhibitor (Roche) and lysed 
by sonication.   
Cell debris were removed by centrifugation for 1h at 14 000 rpm at 4°C.  The lysate was 
mixed with 3 ml of Gluthione Sepharose 4B (GSH) beads (GE Healthcare), pre-washed with 
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lysis buffer.  The mixture was allowed to batch bind for 3h at 4°C with constant rotation.  The 
protein-bound beads were washed with lysis buffer to remove unbound material.  Removal of 
the GST tag from the N-terminal segment of DDX5 1-305 was achieved by proteolytic cleavage 
using recombinant 3C protease (GE Healthcare).  Cleaved protein was further purified by size-
exclusion chromatography using Superdex S200 column (GE Healthcare) pre-equilibrated with 
elution buffer (25 mM Tirs-HCl, pH 7.4, 300 mM NaCl and 0.2 mM DTT).  Peak fractions 
analysed by SDS-PAGE were concentrated to 11 mg/ml using an Amicon Ultra-15 (Millipore) 
filtration device. 
3.3.8 Crystallisation and Data Collection 
Crystals of recombinant DDX5 (1-305) (11 mg/ml) were obtained at 15oC using the sitting-drop 
vapour diffusion method from 1:1 µl of protein and precipitant containing 2% (v/v) Tacsimate, pH 
4.0, 0.1 M BIS-TRIS pH 6.5, and 20% (w/v) polyethylene glycol (PEG) 3350.  Crystals were 
transferred to a reservoir solution containing the precipitant with the addition of 30% glycerol, 
before flash-freezing in liquid nitrogen.  X-ray diffraction data from a single crystal of DDX5 1-
305 was collected at the National Synchrotron Radiation Research Center (NSRRC, Taiwan) on 
beamline 13B1.  Raw data were integrated and scaled using the HKL2000 program suite 
(Otwinowski and Minor 1997). 
3.3.9 Structure Determination and Refinement 
The structure of DDX5 1-305 was determined by the molecular replacement method, using the 
structure of domain I of DDX3X (Hogbom, Collins et al. 2007) (Protein Data Bank (PDB) code 
2I4I) as the search model, with the programme Molrep from CCP4 suite (1994).  The model was 
refined with CNS (Brunger, Adams et al. 1998), and multiple rounds of manual fitting with the 
program O (Jones, Zou et al. 1991) using 2Fo-Fc and Fo-Fc electron density maps.  
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3.3.10 GST Fusion Protein Expression and Purification for Use in GST Pull-
Down Assay 
GST-DDX5 deletion mutants were transformed into Escherichia coli BL21-CodonPlus-RIL 
(Stratagene).  The bacterial cells were cultured in TB with ampicillin (Sigma) 100 μg/ml and 
chloramphenicol (Fluka) 20 μg/ml at 37°C.  The cultures were grown to an absorbance of about 
1 at 600 nm.  The temperature was lowered to 16°C and 0.2 mM of IPTG was added to the 
cultures for the induction of recombinant protein production for 24h.  The bacterial cells were 
harvested by centrifugation at 4000 rpm at 4°C and the cell pellets were stored at -20°C before 
processing.  The pellets were later suspended in lysis buffer (50 mM Tirs-HCl, pH 7.4, 400 mM 
NaCl and 0.2 mM DTT) supplemented with complete EDTA-free protease inhibitor (Roche).  
The cells were lysed by sonication.  Cell debris were removed by centrifugation for 1h at 14 000 
rpm at 4°C.  The lysates were mixed with 100 μl of Gluthione Sepharose 4B (GSH) beads (GE 
Healthcare), pre-washed with lysis buffer.  The mixtures were allowed to bind for 3h at 4°C with 
constant agitation.  Protein-bound beads were washed with lysis buffer to remove unbound 
proteins and resuspended in 1 ml lysis buffer.  GST-tagged H5N1 NS1 protein residues 1-75 
and BLR, a chimeric form of the Mcl-1 protein’s Bcl-2-like region (Czabotar, Lee et al. 2007), 
were similarly expressed after subcloning of the appropriate open reading frames into pGex6P-1 
vectors (YJ Tan, unpublished results). 
3.3.11 In Vitro Translation 
pXJ40myc-DDX5(1-614), pXJ40myc-DDX5(61-614), pXJ40myc-DDX5(79-614) and 
pXJ40flag-NS5B plasmids were used as templates to produce the 35S-labeled proteins 
using the TNT Reticulocyte Lysate System (Promega), according to the manufacturer’s 
protocol. 
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3.3.12 GST Pull-Down Assay 
30 µg of GST and GST fusion proteins bound on GSH beads were washed three times with IP 
buffer.  20 μl of 35S-labeled proteins, diluted with 80 μl IP buffer (PBS with 0.5% Triton X-100, 
0.5% NP40, 1 mM EDTA, 1 mM EGTA and 0.4 mM PMSF), was added to the beads and the 
mixtures were incubated at room temperature for 1h.  The beads were then washed 4 times with 
IP buffer.  SDS-PAGE sample loading dye was added to the beads and the bound proteins were 
eluted from the beads by boiling at 100°C for 5 min.  The samples were resolved on a 10% 
SDS-polyacrylamide gel.  The resolved gel was soaked in a solution of 45% methanol and 10% 
acetic acid for 30 min and then placed in Amplify™ solution for 30 min.  The gel was placed on 
a piece of filter paper, covered with cling wrap and dried for 1h at 80°C in a gel drier.  The 
radiolabelled signals were captured on Amersham Hyperfilm™ (GE Healthcare).   
3.3.13 Antibodies  
The primary and secondary antibodies used in the studies are listed in Table 3.1. 
Table 3.1: List of primary and secondary antibodies used. 
Primary Antibody Type Source 
Rabbit anti-DDX1  
(Catalogue number: BL 2421) 
Polyclonal Bethyl Laboratories, Inc. 
Rabbit anti-DDX5  
(Catalogue number: BL 2462) 
Polyclonal Bethyl Laboratories, Inc. 
Rabbit anti-Myc Polyclonal Santa Cruz Biotechnology 
Mouse anti-Myc Monoclonal Santa Cruz Biotechnology 
Rabbit HA-Probe Polyclonal Santa Cruz Biotechnology 
Mouse anti-β-Actin Monoclonal Sigma 
Rabbit anti-Flag Polyclonal Sigma 
Mouse anti-Flag Monoclonal Sigma 
Secondary Antibody  
Goat anti-mouse HRP Pierce 
Goat anti-rabbit HRP Pierce 
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3.4 Results and Discussion  
3.4.1 DDX5 Contains Two Sites That Can Interact with NS5B Independently 
To characterise the interaction between DDX5 and HCV NS5B and determine which domain or 
domains of DDX5 interact with NS5B, a panel of DDX5 deletion mutants were cloned into the 
pXJ40myc vector for co-immunoprecipitation studies with NS5B (Figure 3.1).  Flag-tagged 
NS5B was expressed in Huh-7, a liver cell line that supports HCV replication, together with myc-
tagged DDX5 proteins (Figure 3.2).  The results showed that there are two non-overlapping 
binding sites in DDX5 which bound to NS5B independently.  One binding site is located in the 
N-terminal half of DDX5 between amino acids 1 to 305 and the other in the C-terminal half of 
DDX5 between amino acids 306 to 614.  In general, the C-terminal containing clones; myc-
DDX5, myc-DDX5 1-305 and myc-DDX5 61-305 showed stronger binding with NS5B when 
compared to the deletion mutants that do not contain the N-terminal half of DDX5.  It was 
observed that the deletion of the first 60 amino acids increased myc-DDX5 61-305’s binding 
affinity to NS5B (Figure 3.2).  Amongst the C-terminal clones of DDX5, myc-DDX5 306-614 
bound NS5B more strongly than myc-DDX5 387-614 and myc-DDX5 480-614 (Figure 3.3).  It is 
possible that the residues before amino acid 387 in DDX5 is involved in its binding with NS5B 
and their deletion weakened the interaction.  Deletions of amino acids 387-479 seemed to 
disrupt the interaction further. 
3.4.2 Amino Acids 61-80 in DDX5 Were Sufficient for Interaction with NS5B 
Myc-DDX5 1-80 was excluded from the previous co-immunoprecipitation study with flag-NS5B 
because it did not express well in Huh-7 cells (data not shown).  A highly transfectable cell line, 
293T, was also used, but the expression level of myc-DDX5 1-80 still did not compare well with 
the other myc-DDX5s (data not shown).  Thus, an alternative method, GST-pull down assay, 
was chosen to determine if the first 80 amino acids of DDX5 could interact with NS5B.  Figure 
3.4 shows the GST-tagged DDX5s were cloned for GST-pull down assay with in-vitro 
transcribed 35S labeled NS5B.   
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Figure 3.2: Co-immunoprecipitation of myc-tagged DDX5s and flag- tagged-NS5B. 200 µg of 
clarified cell lysates were pre-incubated with polyclonal anti-myc antibodies before it was added to 
protein A-agarose beads.  Co-immunoprecipitation of Flag-NS5B was detected by monoclonal anti-
flag antibodies.  20 µg of cell lysates were used to detect expressed proteins.  Top panel: Co-
immunoprecipitation of NS5B with DDX5, DDX51-305, DDX5 61-305 and DDX5 306-614, DDX5 
387-614 and 480-614, but not the GST control.  Middle panel: Expression of Flag-NS5B detected 
by polyclonal anti-flag antibodies.  Bottom panel: Expression of the different myc-tagged proteins 
detected by polyclonal anti-myc antibodies. 
 
  
m
y
c
-D
D
X
5
m
y
c
-D
D
X
5
 1
-3
0
5
m
y
c
-D
D
X
5
 6
1
-3
0
5
m
y
c
-D
D
X
5
 3
0
6
-6
1
4
Flag-NS5B (co-IP)
Flag-NS5B (expression)
myc-tagged proteins (expression)
m
y
c
-G
S
T
m
y
c
-D
D
X
5
 3
8
7
-6
1
4
m
y
c
-D
D
X
5
 4
8
0
-6
1
4
m
y
c
-D
D
X
5
m
y
c
-D
D
X
5
 1
-3
0
5
m
y
c
-D
D
X
5
 6
1
-3
0
5
m
y
c
-D
D
X
5
 3
0
6
-6
1
4
m
y
c
-G
S
T
m
y
c
-D
D
X
5
 3
8
7
-6
1
4
m
y
c
-D
D
X
5
 4
8
0
-6
1
4
 
 
 
 
  Chapter 3 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Co-immunoprecipitation of flag-NS5B with myc-tagged C-terminal DDX5s.  200 
µg of clarified cell lysates were pre-incubated with polyclonal anti-myc antibodies before it was 
added to protein A-agarose beads.  Co-immunoprecipitation of Flag-NS5B was detected by 
monoclonal anti-flag antibodies.  20 µg of cell lysates were used to detect expressed proteins.  Top 
panel: Co-immunoprecipitation of NS5B with DDX5 306-614, DDX5 387-614 and 480-614.  Middle 
panel: Expression of Flag-NS5B detected by polyclonal anti-flag antibodies.  Bottom panel: 
Expression of the different C-terminal myc-tagged DDX5 proteins detected by polyclonal anti-myc 
antibodies. 
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Figure 3.4: DDX5 GST fusion proteins selected for GST pull-down assay. 
 
 
GST-tagged DDX5 1-305, 61-305 and 1-80 were successfully expressed and purified (Figure 
3.5A).  The results from the GST-pull-down assay showed that GST-tagged DDX5 1-305, 61-
305 and 1-80 were all able to pull-down in-vitro transcribed NS5B with GST-DDX5 1-305 
showing the strongest interaction with NS5B (Figure 3.5B).  In contrast, no binding was 
observed when GST alone was used for the pull-down.  The results indicated that residues 61-
80 are sufficient for the interaction between NS5B and DDX5.   
However, it was also observed that the GST pull-down results were inconsistent with the 
previous co-immunoprecipitation results where myc-DDX5 61-305 bound NS5B more strongly 
than myc-DDX5 1-305 (Figure 3.2).  There are two possible reasons why the results from the 
two sets of experiments are different.  One reason may be that NS5B used for GST-pull-down 
was expressed using rabbit reticulocyte and may lack certain co-factors that are available in the 
mammalian cell expression system used for co-immunoprecipitation.  Another reason could be 
that the large GST tag of the bacterial expressed GST-DDX5 1-305 and GST-DDX5 61-305 
may have affected their interaction with NS5B.  This will be further explained in the latter part of 
this chapter.   
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Figure 3.5: GST pull-down of NS5B by DDX5 N-terminal fusion proteins NS5B pulled down 
with DDX5 fusion proteins 1-305, 61-305 and 1-80.  The assay was carried out by mixing 30 µg 
of Glutathione-Sepharose bound fusion protein expressed in E. coli with in vitro translated 
35
S-
labeled NS5B.  Binding results were analysed by SDS-PAGE and autoradiography. A. 30 µg of 
GST fusion proteins used in the pull-down assay was analyszed by SDS-PAGE followed by 
Coomassie blue staining to ascertain the purity of the proteins.  B. In vitro transcribed NS5B was 
pulled down by N-terminal DDX5 fusion proteins DDX5 1-305, DDX5 61-305 and DDX5 1-80, but 
not the GST control.   
 
3.4.3 Domain I of DDX5 is Similar to That of Other DEAD-Box RNA Helicases  
To gain further insight into the interaction between DDX5 and NS5B, DDX5 1-305 and DDX5 
306-614 were expressed as N-terminal GST fusion proteins.  GST was removed with the 3C 
protease and as a consequence 5 amino acids (GPLGS) remained fused to the N-terminal 
domain.  Purification of DDX5 306-614 failed as the protein underwent degradation when 
expressed in E. coli (data shown in Chapter 2).  Purification of DDX5 1-305 was successful and 
crystallization trials were performed (data shown in Chapter 2).  As shown in the GST-pull-down 
assay (Figure 3.5), DDX5 1-305 interacts directly with NS5B and thus represents as a suitable 
target for our structural studies.   
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DDX5 1-305 was found to crystallize in space group I222 and the structure was solved 
by molecular replacement using the structure of domain I of DDX3X (PDB code: 2I4I) and 
refined to the crystallographic R-factor of 0.23 (Rfree 0.29).  One molecule was identified in the 
asymmetric unit.  Due to lack of density, residues 1-50 were not observed.  DDX5 1-305 
contains 8 centrally located -sheets packed against 9 -helices (Figure 3.6).  A structure-
homology search on the Dali server (www.ebi.ac.uk/dali) revealed a high degree of similarity of 
domain I of DDX5 (residues 79-303) with the equivalent domain in human DDX3X (Hogbom, 
Collins et al. 2007), Drosophila VASA (Sengoku, Nureki et al. 2006) and eukaryotic initiation 
factor 4A-I (eIF4a) (Caruthers, Johnson et al. 2000; Sengoku, Nureki et al. 2006) with an rmsd 
of 1.4 Å, 1.7 Å and 1.9 Å, respectively.  
Domain I of DDX5 contains many typical features found in the structures of other DEAD-
box helicases which include the conserved motifs, Q, I (Walker A), II (Walker B, DEAD-box), Ia, 
Ib, and II (Figure 3.6).  A sequence alignment of DDX5 with DDX3X and DDX19B also revealed 
high sequence identity in the conserved motifs of domain I, with the exception for the Q motif 
(Figure 3.7).  For the Q motif, the length varies between the 3 proteins and there are only a few 
identical residues.  The Q motif usually consists of 9 amino acids that include an essentially 
invariant glutamine (Tanner, Cordin et al. 2003).  For DDX5, DDX3X and DDX19B, the invariant 
glutamine is indeed conserved (Figure 3. 7).  As the crystal structures of DDX3X and DDX19B 
have been solved, ribbon representations of these were generated using pymol.  For easy 
comparison, only domain I is used.  The three-dimensional structures showed that domain I of 
DDX5, DDX3X and DDX19B are structurally similar and have a core of 8 β-strands that is 
surrounded by α-helixes (Figure 3.8).  
3.4.4 The ATP Binding Property of DDX5 61-305 Is Not Essential for the 
Interaction with NS5B  
No nucleotide is observed in the ADP/ATP binding site of the crystal structure of DDX5 61-305 
indicating that the apo form of DDX5 61-305 is capable of binding NS5B in vitro (as 
demonstrated by GST-pull down assay in Figure 3.5).  In order to determine if this is true for the 
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interaction between DDX5 1-305 and NS5B in Huh-7 cells, co-immunoprecipitation experiments 
were performed to determine the interaction of two DDX5 substitution mutants (K144N and 
D248N) with NS5B.  A previous study has shown that the K144N substitution abolished ATP-
binding while substitution within the DEAD-box did not have any effect on ATP-binding (Jalal, 
Uhlmann-Schiffler et al. 2007).  Consistent with the results from the GST-pull-down assay, the 
DDX5 61-305K144N substitution mutant bound NS5B to a similar extent as DDX5 61-305 
suggesting that ATP binding is not essential for the interaction (Figure 3.9).  DDX5 61-
305D248N substitution mutant also showed similar binding to NS5B, suggesting that the DEAD-
box (ATPase activity) is also not essential for the interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Structure of DDX5 1-305.  The structure of DDX5-N showing a helix from the 5’-non 
translated region (NTR) and conserved motifs Q, I, Ia,Ib,II and III of domain 1.  The structure of 
DDX5 1-305 was solved by Dr Sujit Dutta. 
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Figure 3.7: Sequence alignment of DDX5 61-305 with DDX3X 132-420 and DDX19 49-300 
showing conserved motifs of DDX5 61-305.  Sequence alignment of DDX5 61-305 (GI: 
2599359) with DDX3x 132-420 (GI: 33873845) and DDX19 49-300 (GI: 3386946) showing 
conserved Q-motif, motif I, motif Ia, motif Ib, motif II and motif III of domain I in boxes.  (*)denotes 
sequence identity, (:) strongly similar and (.) weakly similar   (CLUSTALW multiple alignment 
NPS@: Network Protein Sequence Analysis http://npsa-pbil.ibcp.fr/cgi-bin/align_clustalw.pl) 
3.4.5 Flexible Region in the N-terminal of DDX5 1-305 Auto-Inhibits Its Interaction 
with NS5B  
The highly variable N and C terminal regions of DEAD helicases play crucial roles in their 
regulation.  To understand the mechanism of regulation, DDX5 1-305, which contains both the 
N-terminal flanking region (NTR) and domain I of DDX5, was crystallized and subjected to X-ray 
diffraction (see Chapter 2).  However, due to disorder, only part of the NTR region 51-78 was 
observed in the electron density map.  This region forms an extensive loop and supplements the 
core with an additional -helix (Figure 3.6).   
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Figure 3.8: Structure of DDX5 61-305 and the corresponding domain in DDX3X and DDX19B.  
The structures have been orientated to show the 8 β-strands in the middle surrounded by α-
helixes.  N denotes the N terminal domain of the structure.   
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The co-immunoprecipitation experiments showed that DDX5 61-305 binds NS5B 
stronger than DDX5 1-305 (Figure 3.2), suggesting that the NTR of DDX5 1-305 can auto-inhibit 
its interaction with NS5B.  In our crystal structure, the first 50 residues of the NTR are highly 
disordered while residues 51-69 form an extended loop structure and residues 70-78 form an α-
helix (Figure 3.10).  Unfortunately, the crystal structure does not reveal any contact between the 
NTR and the rest of DDX5 1-305.  This does not rule out that the NTR can fold back on the rest 
of DDX5 1-305, but rather is a reflection of the highly flexible nature of the NTR and the possibly 
highly dynamic nature of the interaction.  Hence, to further investigate the structural elements in 
NTR that are involved in the auto-inhibition, more DDX5 mutants were created for co-
immunoprecipitation with NS5B (Figure 3.10).  The first mutant is DDX5 61-305 in which the N-
terminal part of the NTR has been deleted, but the helix in the NTR remains intact.  The second 
mutant is DDX5 79-305 where the entire NTR has been deleted.  The third mutant is DDX5 1-
305Δ70-78 where the helix in the NTR has been deleted but the flexible first 50 residues and 
the extended loop (residues 51 to 69) remain intact. 
Consistent with the results shown in Figure 3.2, both DDX5 61-305 and DDX5 79-305 
showed higher binding to NS5B than DDX5 1-305 (Figure 3.11), indicating that the auto-
inhibition is abolished when part or the complete NTR is deleted.  The internal deletion mutant 
DDX5 1-305∆70-78 also binds strongly to NS5B (Figure 3.11), indicating that residues 1-69 
cannot cause auto-inhibition in the absence of the helix formed by amino acids 70-78.  This 
suggests that this helix may bring the flexible 1-69 residues of NTR close to the NS5B binding 
site in DDX5 1-305, presumably within residues 79-305.  Overall, the results also showed that 
auto-inhibition involves amino acids 1-78, and the helix formed by amino acid 70-78 is 
necessary for the inhibition to occur (Figure 3.11).  Interestingly, auto-inhibition was also 
observed with DDX19, another DEAD-box helicase in which the flexible N-terminal amino acid 
folds back and auto-inhibits ATPase activity (Collins, Karlberg et al. 2009).  Based on this mode 
of auto-inhibition, it is possible to reconcile the fact that GST-DDX5 1-305 did not bind NS5B to 
a lesser extent than GST-DDX5 61-305 in the GST pull-down assay (Figure 3.5B).  As the auto-
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inhibition requires the NTR to be flexible, the fusion with a large protein GST at the N-terminal of 
NTR could have rendered it rigid and unable to fold onto the NS5B binding site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Co-immunoprecipitation of NS5B with DDX5-N with mutated ATP binding site 
and ATP hydrolysis site.  NS5B co-immunoprecipitated with DDX5 61-305 with a mutated 
ATP binding site as well as DDX5-N with a mutated ATP hydrolysis site.  200 µg of clarified 
cell lysates were pre-incubated with polyclonal anti-myc antibodies before it was added to Protein-
A-agarose beads.  Co-immunoprecipitation of Flag-NS5B was detected by monoclonal anti-flag 
antibodies.  20 µg of cell lysates were used to detect expressed proteins.  Top panel: Co-
immunoprecipitation of NS5B with DDX5 61-305, DDX5 61-305K144N (mutated ATP binding site) 
and DDX5 61-305D248N (mutated ATP hydrolysis site) but not GST control.  Middle panel: 
Expression of Flag-NS5B detected by polyclonal anti-flag antibodies.  Bottom panel: Expression 
of the different myc-tagged proteins detected by polyclonal anti-myc antibodies. 
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Figure 3.10: Map of myc-DDX5 1-305 with modifications in the first 78 amino acids (NTR).  
The first 50 residues of the NTR are highly disordered, followed by an extended loop structure from 
51-69 and an α-helix from amino acids 70-78.  Deletions of the different features were made to 
investigate their function when DDX5 binds NS5B.    
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Figure 3.11: Co-immunoprecipitation of NS5B with the N-terminal half of DDX5 with 
modifications in the first 78 amino acids.  200 µg of clarified cell lysates were pre-incubated with 
polyclonal anti-myc antibodies before it was added to Protein-A-agarose beads.  Co-
immunoprecipitation of Flag-NS5B was detected by monoclonal anti-flag antibodies.  20 µg of cell 
lysates were used to detect expressed proteins.  Top panel: Co-immunoprecipitation of NS5B with 
DDX5 1-305, DDX5 61-305, DDX5 79-305 and DDX5 1- 305 70-78 but not GST control.  Middle 
panel: Expression of Flag-NS5B detected by polyclonal anti-flag antibodies.  Bottom panel: 
Expression of the different myc-tagged proteins detected by polyclonal anti-myc antibodies. 
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3.4.6 DDX5 1-80 Is Able to Interact with DDX5  
In order to gather more insight into the mechanism by which the NTR of DDX5 is involved in the 
auto-inhibition, we sought to demonstrate a direct interaction between the NTR and the rest of 
DDX5 by biophysical analysis.  Thus, attempts were made to express and purify DDX5 1-80.  
GST fusion protein of DDX5 1-80 was successfully expressed in E. coli, but when the 3C 
protease was used to cleave it from its GST tag, extensive degradation occurred as evidenced 
by the appearance of a smear upon separation on SDS-PAGE (Figure 3.12).  Failure to obtain 
untagged and intact DDX5 1-80 meant that it was not possible to measure the affinity of binding 
between DDX5 1-80 and the rest of DDX5 via quantitative measurements like surface plasmon 
resonance or isothermal titration calorimetry assays.  Hence, GST-DDX5 1-80 was used in a 
non-quantitative GST-pull-down assay as described below.  
3.4.7 GST Pull-Down of DDX5 61-305 with GST-DDX5 1-80 
Next, a GST-pull-down assay was performed by using GST-DDX5 1-80 and highly purified 
DDX5 61-305.  The expression and purification of DDX5 61-305 were presented in Chapter 2.  
As shown in Figure 3.13, DDX5 61-305 bound to GST-DDX5 1-80 resulting in the appearance 
of an additional protein band at the molecular weight of DDX5 61-305 after the pull-down.  
However, it was not possible to ascertain if DDX5 61-305 also bound to GST alone because 
GST was similar in molecular weight to DDX5 61-305 and they could not be easily differentiated 
when analysed on SDS-PAGE (Figure 3.13).  As it is possible that DDX5 61-305 bound to both 
GST-DDX5 1-80 and the GST control, the result of this experiment was inconclusive. 
3.4.8 Unspecific Binding of DDX5 61-305 to GST-H5N1 NS1 1-75 and GST-
BLR 
To resolve the problem associated with size similarity of DDX5 61-305 and GST, GST tagged 
H5N1 NS1 protein residues 1-75 and BLR, a chimeric form of the Mcl-1 protein’s Bcl-2-like 
region (Czabotar, Lee et al. 2007) were used as negative controls in the GST-pull-down assay 
of DDX5 1-80 and DDX5 61-305.  It was observed that DDX5 61-305 binding was unspecific as 
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it bound the negative controls H5N1 NS1 1-75 and BLR as well as the intended target DDX5 1-
80 (Figure 3.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Bacterial expression of GST-DDX5 1-80.  DDX5-1-80 was not stable when C3 
protease was used to cleave it from its GST tag, a smearing of DDX5 1-80 was observed.  Lane 1: 
Glutathione-Sepharose bound GST-DDX5 1-80.  Lane 2: Purified DDX5 1-80 after C3 cleavage. 
Lane 3: Protein molecular weight standards.  
3.4.9 Amino Acids 1-80 of DDX5 Are Able to Interact with the Rest of DDX5 
The unspecific binding observed above suggests that the purified DDX5 61-305 may be 
misfolded and/or might have undergone self-aggregation in the buffer used in the GST-pull-
down assay.  To overcome this problem, the GST-pull-down assay was repeated by using rabbit 
reticulocytes to express the DDX5 proteins via in vitro translation.  Such a cell free mammalian 
system has recently been reported to yield numerous proteins in the native form 
G
S
T
-
D
D
X
5
 1
-
8
0
D
D
X
5
 1
-
8
0
P
ro
te
in
 L
a
d
d
e
r
30kDa
15kDa
1 2 3
 
 
 
 
  Human DDX5 Interaction with Hepatitis C Virus NS5B 
 
83 
 
(http://www.promega.com/resources/articles/pubhub/role-of-cell-free-rabbit-reticulocyte-
expression-systems-in-functional-genomics/).   
Using this system, DDX5 1-614 was successfully expressed as a single prominent band 
at the expected molecular weight, as observed after SDS-PAGE (Figure 3.15).  DDX5 61-614 
and DDX5 79-614 were also expressed although they exhibited double bands, indicating that 
some cleavage has occurred (Figures 3.16 and 3.17).  Shorter forms of DDX5 were not 
successfully expressed (data not shown).  GST-pull-down showed that all 3 DDX5 proteins, 
namely, DDX5 1-614, DDX5 61-614 and DDX5 79-614, bound to DDX5 1-80 fused to GST, but 
not by GST alone (Figures 3.15-3.17).  Thus, it has been shown that DDX5 1-80 is capable of 
binding to the rest of DDX5 and this is consistent with our hypothesis that the flexible NTR of 
DDX5 folds back to interact with the NS5B binding site in DDX5 1-305 and causes auto-
inhibition. 
 
 
 
 
 
 
Figure 3.13: GST-pull-down of DDX5 61-305 with GST-DDX5 1-80 with GST as control.  20 µg 
of Glutathione-Sepharose bound fusion protein expressed in E. coli was mixed with 200 µg of 
purified DDX5 61-305.  Binding results were analysed with SDS-PAGE and detected with 
Coomassie staining.  20 µg of each protein used were loaded as reference.  Lane 1: GST 20 µg.  
Lane 2: GST-DDX5 1-80 20 µg.  Lane 3: DDX5 61-305 20 µg.  Lane 4: GST + DDX5 61-305. 
Lane 5: GST-DDX5 1-80 + DDX5 61-305.  
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Figure 3.14: GST pull-down of DDX5 61-305 with GST-DDX5 1-80 with NS1 and BLR as 
controls. 30 µg of Glutathione-Sepharose bound fusion protein expressed in E. coli was mixed 
with 55 µg of purified DDX5 61-305.  Binding results were analysed with SDS-PAGE and detected 
with Coomassie staining.  Top Panel: 3 µg of each protein used were loaded as reference.  
Bottom panel: Lane 1: DDX5 61-305.  Lane 2: Protein molecular weight standards.  Lane 3: GST-
DDX5 1-80 + DDX5 61-305.  Lane 4: GST-H5N1 NS1 1-75 + DDX5 61-305.  Lane 5: GST-BLR + 
DDX5 61-305  
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Figure 3.15: GST pull-down of 
35
S-labelled DDX5 1-614 by GST-DDX5 1-80.  30 µg of 
Glutathione-Sepharose bound fusion protein expressed in E. coli was mixed with in vitro translated 
35
S-labelled DDX5 1-614.  Binding results were analysed by SDS-PAGE and autoradiography.  
Upper panel: 30 µg of Glutathione-Sepharose bound fusion proteins used in the pull-down assay 
was analysed by SDS-PAGE followed by Comassie blue staining to ascertain the purity of the 
proteins.  Lower panel: Lane 3 shows 
35
S-labeled DDX5 1-614 protein bound to DDX5 1-80 but 
not the GST control in lane 2.  One tenth of the binding input was loaded in lane 1. 
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Figure 3.16: GST-pull-down of 
35
S-labelled DDX5 61-614 by GST-DDX5 1-80.  30 µg of 
Glutathione-Sepharose bound fusion protein expressed in E. coli was mixed with in vitro translated 
35
S-labeled DDX5 61-614.  Binding results were analysed by SDS-PAGE and autoradiography.  
Upper panel: 30 µg of Glutathione-Sepharose bound fusion proteins used in the pull-down assay 
was analysed by SDS-PAGE followed by Comassie blue staining to ascertain the purity of the 
proteins.  Lower panel: Lane 3 showed 
35
S-labelled DDX5 61-614 protein bound to DDX5 1-80, 
but not the GST control in lane 2.  One tenth of the binding input was loaded in lane 1. 
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Figure 3.17: GST pull-down of 
35
S-labelled DDX5 79-614 by GST-DDX5 1-80.  30 µg of 
Glutathione-Sepharose bound fusion protein expressed in E. coli was mixed with in vitro translated 
35
S-labeled DDX5 79-614.  Binding results were analysed by SDS-PAGE and autoradiography.  
Upper panel: 30 µg of Glutathione-Sepharose bound fusion proteins used in the pull-down assay 
was analysed by SDS-PAGE followed by Coomassie blue staining to ascertain the purity of the 
proteins.  Lower panel: Lane 3 showed 
35
S-labelled DDX5 79-614 protein bound to DDX5 1-80, 
but not the GST control in lane 2.  One tenth of the binding input was loaded in lane 1. 
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3.4.10 DDX5 Also Interacts with Core and NS3 
In order to determine if DDX5 can interact with other HCV proteins, Myc-tagged DDX5 was co-
transfected into COS-7 cells with Flag-tagged HCV proteins, core, NS3, NS4B, NS5A and 
NS5B.  Flag-GST was co-transfected as a negative control in the co-immunoprecipitation 
experiment.  The transfected cell lysates were analysed using Western blot analysis.  Similar 
expression levels of Myc-DDX5 were detected and the expressions levels of these Flag-tagged 
proteins were also fairly equal (Figure 3.18).  All the HCV proteins migrated to the expected 
molecular weight positions, except NS4B.  Two bands were detected for Flag-NS4B; the bottom 
band at about 30 kDa corresponds to the molecular weight of the protein while the top band is 
probably an oligomeric form of NS4B migrating at a slower rate (Yu, Lee et al. 2006).   The co-
immunoprecipitation results showed that myc-DDX5 bound strongly to Flag-Core 1-173, Flag-
NS3 and Flag-NS5B, and bound weakly to Flag-Core 1-151, Flag-NS4B and Flag-NS5A (Figure 
18). Flag-Core 1-173 bound more strongly than Flag-Core 1-151, which suggested that the 
domain between amino acids 152 and 173 of core is important for its binding to DDX5.  No 
binding was observed for Flag-GST indicating that the protein interactions observed were not 
due to the Myc and Flag tags. 
Of all the HCV proteins, core, NS3 and NS5B show higher binding to DDX5 than NS4B 
and NS5A.  To determine if core, NS3 and NS5B can interact with endogenous DDX5, single 
transfection of Flag-Core 1-173, Flag-NS3 or Flag-NS5B was carried out in COS-7 cells and co-
immunoprecipitations were performed using a rabbit anti-DDX5 polyclonal antibody (Figure 
3.19).  Expression levels of endogenous DDX5 were similar in the samples transfected with 
Flag-Core 1-173, Flag-NS3 and Flag-NS5B.  The Flag-tagged HCV proteins were pulled down 
with endogenous DDX5 when anti-DDX5 antibodies were used for the co-immunoprecipitation 
with Protein-A-agarose beads.  None of the HCV proteins co-immunoprecipitated when an 
irrelevant antibody (anti-HA) was used for the co-immunoprecipitation, indicating that the 
interactions between endogenous DDX5 and the HCV proteins are specific.  Thus, besides the 
interaction between DDX5 and NS5B, our results show that DDX5 can also interact specifically 
with core 1-173 and NS3.   
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Figure 3.18: Co-immunoprecipitation of DDX5 with HCV proteins Core 1-151, Core 1-173, 
NS3, NS4B, NS5A and NS5B.  200 µg of co-transfected cell lysates were incubated at room 
temperature with 20 μl of pre-washed ANTI-FLAG® M2 affinity gel (Sigma).  Co-
immunoprecipitation of myc-DDX5 was detected by polyclonal anti-myc antibodies.  10 µg of cell 
lysates were used to detect expressed proteins.  Top panel: Co-immunoprecipitation of myc- 
DDX5 with Flag-Core 1-151, Flag-Core1-173, Flag-NS3, Flag-NS4B, Flag-NS5A or Flag-NS5B, but 
not GST control.  Middle panel: Expression of myc-DDX5 detected with polyclonal anti-myc 
antibodies.  Bottom panel: Expression of the different Flag-tagged proteins detected with 
polyclonal anti-flag antibodies. 
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Figure 3.19. Co-immunoprecipitation of Core 1-173, NS3, and NS5B with endogenous DDX5.  
COS-7 cells transfected with Flag-Core 1-173, Flag-NS3 or Flag-NS5B were co-
immunoprecipitated with endogenous DDX5.  200 µg of clarified cell lysates were pre-incubated 
with polyclonal anti-DDX5 or anti-HA antibodies before it was added to Protein-A-agarose beads. 
10 µg of cell lysates were used to detect expressed proteins.  A. Expression of endogenous DDX5 
in COS-7 cells transfected with Flag-Core 1-173, Flag-NS3 or Flag-NS5B detected with anti-DDX5 
antibody.  B, C, and D.  Flag-core, NS3 and NS5B co-immunoprecipitated with endogenous DDX5 
when anti-DDX5 antibodies were used for IP, but not when anti-HA antibodies were used.  Co-
immunoprecipitation of Flag-tagged proteins were detected by monoclonal anti-flag antibodies.  
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3.5 Conclusion  
In the past decade a growing number of DEAD-box RNA helicase structures have been 
determined (Caruthers, Johnson et al. 2000; Carmel and Matthews 2004; Shi, Cordin et al. 
2004; Sengoku, Nureki et al. 2006; Hogbom, Collins et al. 2007).  They contain a central region 
comprising of 2 conserved domains, termed domain I and II, flanked by highly variable N- and 
C-terminal sequences.  Comparison of known structures of domain I and II reveal they have a 
fold belonging to the RecA super family, where 5 -strands are surrounded by 5 -helices (Story 
and Steitz 1992).  We have previously shown that DDX5, a human RNA helicase belonging to a 
large family of DEAD-box RNA helicases, interacts with NS5B and that the C terminus of NS5B 
is essential for this interaction (Goh, Tan et al. 2004).  Co-immunoprecipitation experiments 
showed there are 2 independent NS5B binding sites in DDX5, one in the N-terminal half 
(corresponding to residues 1 to 305 of DDX5) and the other in the C-terminal half 
(corresponding to residues 306 to 614 of DDX5) (Figures 2 and 3).  Interestingly, DDX5 1-305 
and DDX5 306-614 contain the conserved domain I and II respectively.   
Using DDX5 1-305, the crystal structure of the apo form of the N-terminal half of DDX5 
(residues 55-303) was solved in this study and it reveals that domain I of DDX5 contains many 
typical features found in the structures of other DEAD-box helicases (Figure 3.6).  A sequence 
alignment of DDX5 with DDX3X and DDX19B also revealed high sequence identity in the 
conserved motifs, namely, I (Walker A), II (Walker B, DEAD-box), Ia, Ib, and II (Figure 3.7) and 
the three-dimensional structures showed that domain I of all three proteins are structurally 
similar (Figure 3.8).  
The bacterially expressed and purified DDX5 1-305 is in its apo form as there is no 
bound ATP observed in the crystal structure as would be expected since no nucleotide 
supplement was added to the growth medium.  This form of DDX5 1-305 is capable of binding 
NS5B, suggesting that the ATPase activity of DDX5 is not involved in the interaction (Figure 
3.5).  Consistently, co-immunoprecipitation experiments using Huh-7 cells confirmed that both 
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the ATP-binding and the DEAD motif in DDX5 1-305 are also not required for interaction with 
NS5B (Figure 3.9). 
The NTRs of DEAD-box helicases are highly variable and there is limited structural 
information (Cordin, Banroques et al. 2006; Fuller-Pace 2006).  For DDX5 1-305, no density 
was observed for residues 1-50 within the NTR.  Analysis, using the protein disorder server 
RONN (Yang, Thomson et al. 2005), predicted this region to be disordered as is observed with 
other DEAD-box helicases.  The remaining part of the NTR (residues 51 to 78) is composed of a 
loop and an α-helix located before domain I (Figure 3.6).  To our knowledge, this is only the 
second report of structural elements in the NTR of DEAD-box RNA helicases as most of the 
structures of DEAD-box RNA helicases were obtained using proteins expressed without the 
NTR.  The first report documented an α-helix in the NTR of DDX19 which inserts between 
domains I and II to inhibit ATP hydrolysis, unless it is displaced by RNA binding (Collins, 
Karlberg et al. 2009).  Remarkably, our results show that the NTR of DDX5 1-305 inhibits its 
interaction with NS5B (Figures 3.2 and 3.11).  The -helix (residues 70-78) in the NTR is 
essential for this auto-inhibition and seems to mediate the interaction between the highly flexible 
1-70 residues in NTR and NS5B binding site in DDX5 1-305 (Figure 3.11), presumably located 
within residues 79-305.  Furthermore, DDX5 1-80 can bind directly to full-length DDX5 as well 
as DDX5 with part or all of the NTR deleted (Figures 3.15-3.17), which provide further evidence 
that the flexible NTR of DDX5 folds back to interact with the NS5B binding site. 
Our results suggest that the N-terminal (DDX5 1-305) and C-terminal (DDX5 306-614) 
domains of DDX5 interact with NS5B independently.  The high-resolution three-dimensional 
structure of the apo form of DDX5 1-305 provides a basis for future studies to define the precise 
role of DDX5 during HCV infection.  Crystallization of full-length DDX5 and the DDX5-NS5B 
complex is also actively being pursued.  Our data also reveal that the interaction between DDX5 
1-305 and NS5B is auto-inhibited by the highly flexible NTR of DDX5 1-305.  It is expected that 
solving the structure of full-length DDX5 can help ascertain whether the α-helix in the NTR of 
DDX5 can also insert between domains I and II like DDX19. 
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Recent studies revealed that the DEAD-box RNA helicases DDX3, rck/p54 and RNA 
helicase A are required for HCV RNA replication (Ariumi, Kuroki et al. 2007; He, Tang et al. 
2008; Scheller, Mina et al. 2009).  Our previous study also showed that knockdown of 
endogenous DDX5 by RNA interference reduces the transcription of negative-strand HCV RNA 
(Goh, Tan et al. 2004).  It is interesting that multiple DEAD-box RNA helicases are important for 
HCV replication and further studies are warranted to determine if they are involved in the same 
step(s) of the viral life-cycle.  It is also possible that these host proteins are involved in more 
than one viral-host interaction, for example, DDX3 not only binds the HCV core protein, but is 
probably associated with an HCV non-structural protein or HCV RNA itself (Owsianka and Patel 
1999; Ariumi, Kuroki et al. 2007).  In this study, we also showed that besides NS5B, core and 
NS3 can also interact with DDX5 in mammalian cells (Figures 3.18 and 3.19).  Further 
investigations are needed to determine the mechanisms of interaction between DDX5 and 
NS5B, DDX5 and core, DDX5 and NS3, and the impact of these interactions on HCV replication 
by using the infectious clone system based on JFH-1 genotype 2a HCV (Wakita, Pietschmann 
et al. 2005).  Since the three-dimensional structures of NS3 and NS5B have been solved, the 
high-resolution three-dimensional structure of DDX5 1-305 obtained in this study can also be 
used in computer-assisted structure-based molecular-docking to identify critical contacts 
between the interacting proteins.  
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Currently there is no approved vaccine for HCV prevention.  Approximately 3-4 million newly 
HCV infected cases are added yearly to the more than 170 million existing cases world-wide.  
HCV is a significant healthcare burden because of its high treatment cost associated with 
interferon and ribavirin, and at least 10% of infected individuals may develop persistent and 
chronic infection which leads to cirrhosis and liver cancer (Roohvand and Kossari 2011). 
In our study, we aimed to characterize the interaction between host DEAD-box RNA 
helicase DDX5 and NS5B, an RNA-dependent RNA polymerase of HCV, using molecular 
biology techniques and structural analysis.   
Firstly, co-immunoprecipitation results showed that NS5B can bind to DDX5 at two 
independent regions.  In the process of testing GST fusion protein expression of DDX5 and its 
panel of deletion mutants in E.coli, it was found that overnight induction at a lower temperature 
(16 or 18oC) and high salt buffer (400 mM NaCl) conditions for extraction and processing of the 
recombinant proteins produced a higher yield.  It was also found that the C-terminal end of 
DDX5 was not stable when purified.  Full-length DDX5 and deletion mutants which contained 
the C-terminal end showed signs of degradation or truncation when purified. 
Fast protein liquid chromatography was used to purify large quantities of selected DDX5 
and NS5B protein for crystallization and co-crystallization trials.  Chemical conditions which 
showed some crystal growth were refined for improved crystallization.  Crystals of DDX5 1-305 
was successfully grown and collected under such refined conditions.   
Native data of these crystals were collected and solved by Dr Sujit Dutta by molecular 
replacement using the structure of domain I of DDX3X.  The solved structure of DDX5 1-305 
(residues 55-303) showed high structural homology with other DEAD-box helicases and 
sequence alignment with DDX3X and DDX19B revealed sequence identity in the conserved 
motifs of Domain I.  The first 50 residues of DDX5 1-305 was not observed due to low density, 
residues 51-69 formed an extended loop structure, residues 70-78 formed an α-helix, followed 
by 8 centrally located β-sheets packed against 9 α-helices.  Co-immunoprecipitation results 
showed that residues 1-78 are required for auto-inhibition of DDX5’s interaction with NS5B.  
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GST pull-down assay of in-vitro transcribed 35S-labeled NS5B showed that amino acids 
61-80 of DDX5 were sufficient for interaction with NS5B.  Co-immunoprecipitation results 
suggested that ATP binding and ATPase activity was not essential for the interaction between 
DDX5 and NS5B and that the flexible N-terminal flanking region of DDX5 1-305 auto-inhibited 
its interaction with NS5B.  GSTpull-down of 35S-labeled DDX5 1-614, DDX5 61-614 and DDX5 
79-614 showed that GST-DDX5 1-80 was able to interact with DDX5, providing further evidence 
that there is auto-inhibition in the interaction between DDX5 1-305 and NS5B. 
Besides NS5B, co-transfected DDX5 was found to interact with HCV’s Core 1-151, Core 
1-173, NS3, NS4B and NS5A.  Transfected HCV Core 1-173, NS3 and NS5B proteins were 
found to interact specifically with endogenous DDX5. 
A successful virus infection requires the evasion of host immune response and the 
recruitment of host factors for propagation.  In this thesis, we explored the interaction between 
HCV NS5B and DDX5.  The findings will add to the basic understanding of HCV replication and 
may aid future studies towards more efficacious drug and vaccine development.  
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APPENDIX 1 
List of Primers Used in the Generation of DDX5 Constructs 
Primers Primer sequence 5’- 3’ AT* (οC) 
DDX5-1F CGGGATCCATGTCGGGTTATTCGAGTGACCGAGAC 79.85 
DDX5-43F CGGGATCCAAAAAGAAGTGGAATCTTGATGAGCTG 75.44 
DDX5-61F# CGGGATCCAAGGAAATTACAGTTAGAGGTCACAAC 72.01 
DDX5-72F CGGGATCCGAGGTGGAAACATACAGAAGAAGC 74.80 
DDX5-80F CGGGATCCGAGCACCCTGATTTGGCTAGGCGCACA 85.03 
DDX5-132F CGGGATCCTTGGATATGGTTGGAGTGGCACAGACT 78.40 
DDX5-163F CGGGATCCGAGAGAGGCGATGGGCCTATTTGTTTG 80.89 
DDX5-204F CGGGATCCGGTGGTGCTCCTAAGGGACCACAAATA 80.04 
DDX5-306F CGGGATCCGAACTGAGTGCAAACCACAACATTCTT 77.72 
DX5-406F CGGGATCCGATGTGGAAGATGTGAAATTTGTCATC 76.70 
DDX5-80R CCGCTCGAGTTACTTGCTTCTTCTGTATGTTTCCA 73.30 
DDX5-305R# CCGCTCGAGTTAAAGTGCACCAATGTTTATATGAA 71.95 
DDX5-391R CCGCTCGAGTTATTTTCCATGTTTGAATTCATTTA 71.10 
DDX5-409R CCGCTCGAGTTAATCTTCGACCAACTGAAGCAACT 75.29 
DDX5-411R CCGCTCGAGTTATTTCACATCTTCCACATCTAGCC 74.18 
DDX5-434R CCGCTCGAGTTAGCGAGCAGTTCTTCCAATTCGAT 77.59 
DDX5-480R CCGCTCGAGTTATGAACCTCTGTCTTCGACCAACT 75.57 
DDX5-574R CCGCTCGAGTTAGCTATCATAACCATTCTGGTAAG 70.64 
DDX5-614R CCGCTCGAGTTATTGGGAATATCCTGTTGGCATTG 76.59 
DDX5-del70-78-F GCACAGCAAGCAAGGAAATTACAGTTAG 64.85 
DDX5-del70-78-F2 GGCGCACAGCAAGCAAGGAAATTACAGTTAG 72.02 
DDX5-79F CGGGATCCAGCAAGGAAATTACAGTTAGAGG 70.53 
DDX5-del70-78-R TCCTTGCTTGCTGTGCGCCTAGCCAAATC 75.94 
DDX5-K114N-F GGGAACACATTGTCTTATTTGCTTCC 63.64 
DDX5-K114N-R CAATGTGTTCCCAGATCCAGTCTGTG 66.60 
*AT, annealing temperature; #mycDDX5-(61-305)D248N was generated using pFG384, pSG-myc-p68 (D248N) (Goh, 
Tan et al. 2004) as a template with forward and reverse primers DDX5-61F and DDX5-305R. 
 
 
 
 
